

chain nodes :

17 18

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 19 20 21 22 23 24

chain bonds :

7-11 14-17 17-18 18-19

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13  
13-14 14-15 15-16 19-20 19-24 20-21 21-22 22-23 23-24

exact/norm bonds :

5-7 6-9 7-8 7-11 8-9 11-12 11-16 12-13 13-14 14-15 14-17 15-16  
17-18 18-19

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 19-20 19-24 20-21 21-22 22-23 23-24

G1:O, S, N

G2:N, CH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS  
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom

09/712,129

=> d his

(FILE 'HOME' ENTERED AT 14:51:00 ON 05 DEC 2001)

FILE 'REGISTRY' ENTERED AT 14:51:06 ON 05 DEC 2001

L1 STRUCTURE uploaded  
L2 QUE L1  
L3 13 S L2  
L4 269 S L2 SSS FUL

FILE 'CAPLUS' ENTERED AT 14:53:17 ON 05 DEC 2001

L5 43 S L4  
L6 20 S L5 AND JOURNAL/DT  
L7 0 S L6 AND 2001/SO  
L8 4 S L6 AND 2000/SO  
L9 3 S L6 AND 1999/SO  
L10 2 S L6 AND 1998/SO  
L11 2 S L6 AND 1997/SO  
L12 2 S L6 AND 1996/SO  
L13 5 S L6 AND 1995/SO  
L14 0 S L6 AND 1994/SO  
L15 1 S L6 AND 1993/SO  
L16 19 S L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15

FILE 'STNGUIDE' ENTERED AT 14:57:19 ON 05 DEC 2001

FILE 'CAPLUS' ENTERED AT 15:04:09 ON 05 DEC 2001


L17 24 S L5 NOT L16

=> d bib abs hitstr 1-24

09/712,129

ANSWER 1 OF 24 CAPLUS COPYRIGHT 2001 ACS  
2001:617978 CAPLUS  
DN 135:195564  
TI Preparation of phenoxyalkylamine derivatives useful as opioid .delta. receptor agonists  
IN Tsushima, Masaki; Tadauchi, Kaori; Asai, Kenji; Miike, Naoko; Imai, Masako; Kudo, Toshiaki  
PA Meiji Seika Kaisha, Ltd., Japan  
SO PCT Int. Appl., 152 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001060796	A1	20010823	WO 2001-JP1116	20010216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI JP 2000-40791	A	20000218		
OS	MARPAT	135:195564		
GT				




AB The title compds. I [X is a group represented by the general formula R7R8NCO, etc.; A is a satd. or unsatd. 3- to 6-membered carbocyclic group or the like; B is CH<sub>2</sub> or the like; n is 0 to 2; R<sub>1</sub> is hydrogen, halogeno, or the like; R<sub>2</sub>, R<sub>3</sub>, and R<sub>7</sub>, R<sub>8</sub> are each hydrogen, optionally substituted lower alkyl, or the like; R<sub>4</sub> is hydrogen, optionally substituted lower alkyl, or the like; R<sub>5</sub> is hydrogen, halogeno, or the like; and R<sub>6</sub> is a satd. or unsatd. mono- or bicyclic carbocyclic group or the like, or alternatively, R<sub>5</sub> and R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> may be united to form a cyclic structure] are prep'd. In an in vitro test for affinity for the .delta. opioid receptors, 1-[2-[2-(4-isobutyloxycarbonylbenzyl)phenoxy]ethyl]-4-(2-hydroxymethyl-1H-benzimidazol-1-yl)piperidine showed the Ki value of 73 nM.

IT 356071-63-1P 356071-64-2P  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of phenoxyalkylamine derivs. useful as opioid .delta. receptor agonists)

RN 356071-63-1 CAPLUS


09/712,129

CN Benzamide, N,N-diethyl-4-[[2-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 356071-64-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[[2-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 20

RE

- (1) Eli Lilly And Company; JP 06-56892 A CAPLUS
- (2) Eli Lilly And Company; CN 1080926 A CAPLUS
- (3) Eli Lilly And Company; CA 2091663 A CAPLUS
- (4) Eli Lilly And Company; RU 2129562 C1 CAPLUS
- (5) Eli Lilly And Company; US 5932543 A CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/712,129

~~DN~~ 7 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2001 ACS  
~~AN~~ 2001:208282 CAPLUS  
~~DN~~ 134:237472  
TI Preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine  
D4 antagonists  
IN Fink, David M.; Freed, Brian S.; Hrib, Nicholas J.; Kosley, Raymond W.,  
Jr.; Lee, George E.; Merriman, Gregory H.; Rauckman, Barbara S.  
PA Aventis Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 157 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019833	A1	20010322	WO 2000-US24962	20000913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-396081 A1 19990914

OS MARPAT 134:237472

AB RZ0CH2CR1R2CH2NR3R4 [I; R = e.g., thieno[2,3-d]isoxazol-3-yl; R1 = OH or  
alkoxy; R2, R4 = H or alkyl; R3 = CH2R5, CH2CH(OH)R5, indanyl, etc.; R5 =  
cyclohex(en)yl, (hetero)aryl, etc.; Z = phenylene] were prepd. Thus,  
3-bromothiophene was acylated by 3-(MeO)C6H4COCl and the oximated product  
cyclized to give, after O-demethylation, 3-RC6H4OH [R =  
thieno[2,3-d]isoxazol-3-yl] which was etherified by (R)-glycidyl tosylate  
and the product aminated by PhCHMeNH2 to give (R)-3-  
RC6H4OCH2CH(OH)CH2NMeCH2Ph (R as above). Data for biol. activity of I  
were given.

IT 330650-07-2P 330650-08-3P 330650-09-4P  
330650-10-7P 330650-11-8P 330650-12-9P  
330650-66-3P 330650-95-8P 330650-97-0P  
330672-15-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)


(prepn. of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4  
antagonists)

RN 330650-07-2 CAPLUS

CN 1-Piperazineethanol, 4-(6-fluoro-1H-indazol-3-yl)-.alpha.-[(3-thieno[2,3-  
d]isoxazol-3-ylphenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


*no US filing*



RN 330650-08-3 CAPLUS

CN 1-Piperazineethanol, 4-(5-methoxy-1H-indazol-3-yl)-.alpha.-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330650-09-4 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330650-10-7 CAPLUS

CN 1-Piperidineethanol, 4-(6-chloro-1,2-benzisoxazol-3-yl)-.alpha.-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330650-11-8 CAPLUS

CN 1-Piperazineethanol, 4-[(1,2-benzisothiazol-3-yl)-.alpha.-[(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330650-12-9 CAPLUS

CN 1-Piperidineethanol, 4-[(6-fluoro-1,2-benzisothiazol-3-yl)-.alpha.-[(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330650-66-3 CAPLUS

CN 1-Piperidineethanol, 4-[(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[(4-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330650-95-8 CAPLUS

1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-methyl-.alpha.-[(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


### Absolute stereochemistry.



RN 330650-97-0 CAPLUS

CN 1,2-Benzisoxazol-6-ol, 3-[4-[(2R)-2-hydroxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 330672-15-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-(1,2-benzisoxazol-3-yl)-.alpha.-[(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2

RE

(1) Duphar International Research B V; WO 9940067 A 1999 CAPLUS  
(2) Hoechst-Roussel Pharmaceuticals Inc; EP 0221414 A 1987 CAPLUS

09/712,129

~~ANSWER 3 OF 24 CAPLUS COPYRIGHT 2001 ACS~~  
2001:208270 CAPLUS  
134:237471  
Preparation of 3-[(aminoalkoxy)phenyl]benzo[d]isoxazoles and analogs as dopamine D4 antagonists  
Shutske, Gregory M.; Hendrix, James A.; Jurcak, John G.; Freed, Brian S.; Hrib, Nicholas J.; Tomer, John D., IV; Hanna, Reda G.  
Aventis Pharmaceuticals Inc., USA  
PCT Int. Appl., 206 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE


PI	WO 2001019821	A1	20010322	WO 2000-US24961	20000913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-395937 A1 19990914

OS MARPAT 134:237471

GI

*no listing*



AB RZOZ1NR3R4 [I; R = e.g., (halo)benzo[d]isoxazol-3-yl; R3 = (hetero)aryl(alkyl), etc.; R4 = H or alkyl; NR3R4 = heterocyclyl; Z = phenylene; Z1 = (CH2)2-3, CH2CH(OR2)CH2, etc.; R2 = H or alkyl] were prep'd. Thus, Ph(CH2)3Br was aminated by piperidine and the product acylated by 2,4-F2C6H3COCl to give, after oximation, 2,4-F2C6H3C(:NOH)C6H4[O(CH2)3NR3R4]-4 [R3R4 = (CH2)5] which was cyclized to give title compd. II. Data for biol. activity of I were given.

IT 330669-13-1P 330669-14-2P 330669-19-7P

330669-29-9P 330669-34-6P 330669-90-4P

330669-91-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prep'n. of 3-[(aminoalkoxy)phenyl]benzo[d]isoxazoles and analogs as dopamine D4 antagonists)


RN 330669-13-1 CAPLUS

CN 1-Piperazineethanol, .alpha.-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)phenoxy)methyl]-4-(1H-indazol-3-yl)-, (.alpha.R)- (9CI) (CA INDEX

09/712,129

NAME)

Absolute stereochemistry.




RN 330669-14-2 CAPLUS

CN 1-Piperidineethanol, 4-[(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)phenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—F

RN 330669-19-7 CAPLUS

CN 1-Piperazineethanol, .alpha.-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)phenoxy)methyl]-4-(6-fluoro-1H-indazol-3-yl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—F

RN 330669-29-9 CAPLUS

CN 1-Piperazineethanol, .alpha.-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)phenoxy)methyl]-4-(1H-indazol-3-yl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330669-34-6 CAPLUS

CN 1-Piperazineethanol, .alpha.-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)phenoxy)methyl]-4-(6-fluoro-1H-indazol-3-yl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—F

RN 330669-90-4 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[ (3-isoxazolo[5,4-b]pyridin-3-ylphenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330669-91-5 CAPLUS

CN 1-Piperazineethanol, 4-(6-fluoro-1H-indazol-3-yl)-.alpha.-[ (3-isoxazolo[5,4-b]pyridin-3-ylphenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11

RE



- (1) Adir; EP 0811622 A 1997 CAPLUS
- (2) Baker, R; US 5576319 A 1996 CAPLUS
- (3) Hoechst Roussel Pharma; EP 0474012 A 1992 CAPLUS
- (4) Hoechst Roussel Pharma; EP 0509402 A 1992 CAPLUS
- (5) Hrib, N; US 5225412 A 1993 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 2001:185749 CAPLUS  
 134:237469  
 Preparation and use of alkylpiperidinylbenzo[d]isoxazole derivatives  
 having psychotropic activity  
 Barkoczy, Jozsef; Gacsalyi, Istvan; Balazs, Laszlo; Levay, Gyoergy; Simig,  
 Gyula; Schmidt, Eva; Pallagi, Katalin; Szenasi, Gabor; Doman, Imre; Greff,  
 Zoltan; Kotay-Nagy, Peter; Ratkai, Zoltan; Seres, Peter  
 Egis Gyogyszergyar Rt., Hung.  
 PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*no US filing*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001017993	A1	20010315	WO 2000-HU96	20000907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI HU 1999-3042	A	19990909		
HU 1999-3043	A	19990909		
OS MARPAT 134:237469				
GI				




AB Compds. of formula I and their prepn. are claimed [wherein; Z is H or OH; n is 0 or 1; X, Y are H; R is H, halo, C1-C6 alk(ox)yl; X', Y' are H, halo, C1-C6 alk(ox)yl or form together to make a 5-7 membered (arom.) or (un)satd. (hetero)cyclic ring that can be fused with one or more 5-7 membered arom. or (un)satd. (hetero)cyclic ring. Alternatively; R, X', Y' are H and X, Y together form a ring system as described above]. The general process claimed is illustrated by the synthesis of compd. II. 6-Fluoro-3-(piperidin-4-yl)benzo[d]isoxazole was alkylated with 1-bromo-3-chloropropane to yield 3-(1-(3-chloropropyl)piperidin-4-yl)-6-fluorobenzo[d]isoxazole. The isoxazole intermediate was treated with 5-hydroxybenzo[c][1,2,5]thiadiazole and base to yield II (43 examples of I were provided). Compds. I showed 5-HT2a antagonist activity by inhibiting DOI-induced hyperthermia; MED of II was 3 mg/kg p.o. (male Wistar rat). Compds. I exhibited antipsychotic effects in their ability to inhibit apomorphine-induced climbing (male MRI mice) at a dose significantly lower than chlorpromazine or clozapine. I also inhibited apomorphine-induced stereotypes at a higher dose than climbing; ratios of 2-23 vs. 3.0 for clozapine and 1.1 for chlorpromazine were obsd. Compds. of the invention displayed anxiolytic activity comparable to buspirone.

IT 329977-28-8P 329977-29-9P 329977-33-5P  
 329977-34-6P 329977-35-7P, 6-Fluoro-3-[1-(3-(7-methoxynaphthalen-2-yloxy)propyl)piperidin-4-yl]benzo[d]isoxazole  
 329977-36-8P, 1-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-3-(6-methoxynaphthalen-2-yloxy)propan-2-ol 329977-38-0P,  
 1-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-3-(2-methylbenzoxazol-6-yloxy)propan-2-ol 329977-39-1P, 6-Fluoro-3-[1-(3-(2-methylbenzoxazol-6-yloxy)propyl)piperidin-4-yl]benzo[d]isoxazole  
 329977-40-4P, 1-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-3-(2-methylbenzoxazol-5-yloxy)propan-2-ol 329977-44-8P,  
 6-Fluoro-3-[1-(2-(2-methylbenzoxazol-6-yloxy)ethyl)piperidin-4-yl]benzo[d]isoxazole 329977-50-6P, 6-Fluoro-3-(1-(2-naphthalene-1-yloxyethyl)piperidin-4-yl)benzo[d]isoxazole 329977-52-8P  
 329977-55-1P, 1-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-3-(2-methoxyphenoxy)propan-2-ol  
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. and use of alkylpiperidinylbenzo[d]isoxazole derivs. having psychotropic activity)


RN 329977-28-8 CAPPLUS

CN 1-Piperidineethanol, .alpha.-[(1,3-benzodioxol-5-yloxy)methyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)- (9CI) (CA INDEX NAME)




RN 329977-29-9 CAPPLUS

CN 1,2-Benzisoxazole, 3-[1-[3-(1,3-benzodioxol-5-yloxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 329977-33-5 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-(2-naphthalenyloxy)methyl- (9CI) (CA INDEX NAME)




RN 329977-34-6 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-([(7-methoxy-2-naphthalenyl)oxy]methyl)- (9CI) (CA INDEX NAME)




RN 329977-35-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[(7-methoxy-2-naphthalenyl)oxy]propyl]-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 329977-36-8 CAPLUS


CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-([(6-methoxy-2-naphthalenyl)oxy]methyl)- (9CI) (CA INDEX NAME)



RN 329977-38-0 CAPLUS


09/712,129

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[[ (2-methyl-6-benzoxazolyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 329977-39-1 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[ (2-methyl-6-benzoxazolyl)oxy]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329977-40-4 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[[ (2-methyl-5-benzoxazolyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 329977-44-8 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[2-[ (2-methyl-6-benzoxazolyl)oxy]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 329977-50-6 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[2-(1-naphthalenyloxy)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 329977-52-8 CAPLUS


CN 1-Piperidineethanol, .alpha.-[(9H-carbazol-4-yloxy)methyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)-, (2E)-2-butehedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 329977-51-7

CMF C27 H26 F N3 O3

PAGE 1-A







CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E

Double bond geometry as shown.



RN 329977-55-1 CAPLUS  
 CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[(2-methoxyphenoxy)methyl]-(9CI) (CA INDEX NAME)



IT 329977-30-2P 329977-37-9P, 6-Fluoro-3-[1-(3-(6-methoxynaphthalen-2-yloxy)propyl)piperidin-4-yl]benzo[d]isoxazole  
 329977-41-5P 329977-42-6P 329977-43-7P,  
 6-Fluoro-3-[1-(2-(7-methoxynaphthalen-2-yloxy)ethyl)piperidin-4-yl]benzo[d]isoxazole 329977-45-9P 329977-46-0P  
 329977-47-1P 329977-48-2P 329977-49-3P,  
 6-Fluoro-3-(1-(3-naphthalene-1-yloxypropyl)piperidin-4-yl)benzo[d]isoxazole hydrochloride 329977-53-9P,  
 4-[3-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy]-9H-carbazole 329977-54-0P, 3-[2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethoxy]-9H-carbazole 329977-56-2P,  
 6-Fluoro-3-[1-(2-(2-methoxyphenoxy)ethyl)piperidin-4-yl]benzo[d]isoxazole hydrochloride 329977-57-3P, 1-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-3-(2-isopropoxyphenoxy)propan-2-ol 329977-58-4P  
 , 6-Fluoro-3-[1-(3-(2-isopropoxyphenoxy)propyl)piperidin-4-yl]benzo[d]isoxazole hydrochloride 329977-59-5P,  
 6-Fluoro-3-[1-(2-(2-isopropoxyphenoxy)ethyl)piperidin-4-yl]benzo[d]isoxazole hydrochloride 329977-60-8P,  
 1-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-3-(4-chloronaphthalen-1-yloxy)propan-2-ol hydrochloride 329977-61-9P,  
 3-[1-(3-(4-Chloronaphthalen-1-yloxy)propyl)piperidin-4-yl]-6-fluorobenzo[d]isoxazole hydrochloride 329977-62-0P,


3-[1-(2-(4-Chloronaphthalen-1-yloxy)ethyl)piperidin-4-yl]-6-fluorobenzo[d]isoxazole hydrochloride **329977-63-1P**  
**329977-64-2P**, 6-Fluoro-3-[1-(3-(4-methoxynaphthalen-1-yloxy)propyl)piperidin-4-yl]benzo[d]isoxazole hydrochloride  
**329977-65-3P**, 6-Fluoro-3-[1-(2-(4-methoxynaphthalen-1-yloxy)ethyl)piperidin-4-yl]benzo[d]isoxazole **329977-66-4P**,  
1-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-3-(7-fluoronaphthalen-1-yloxy)propan-2-ol hydrochloride **329977-67-5P**,  
6-Fluoro-3-[1-(3-(7-fluoronaphthalen-1-yloxy)propyl)piperidin-4-yl]benzo[d]isoxazole hydrochloride **329977-68-6P**,  
6-Fluoro-3-[1-(2-(7-fluoronaphthalen-1-yloxy)ethyl)piperidin-4-yl]benzo[d]isoxazole **329977-69-7P**, 1-(4-(6-  
Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-3-(7-methoxynaphthalen-1-yloxy)propan-2-ol hydrochloride **329977-70-0P**,  
6-Fluoro-3-[1-(3-(7-methoxynaphthalen-1-yloxy)propyl)piperidin-4-yl]benzo[d]isoxazole **329977-71-1P**, 6-Fluoro-3-[1-(2-(7-  
methoxynaphthalen-1-yloxy)ethyl)piperidin-4-yl]benzo[d]isoxazole **329977-72-2P**, 6-Fluoro-3-(1-(3-naphthalene-1-yloxypropyl)piperidin-4-  
yl)benzo[d]isoxazole

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and use of alkylpiperidinylbenzo[d]isoxazole derivs. having psychotropic activity)


RN 329977-30-2 CAPLUS

CN 1,2-Benzisoxazole, 3-[1-[2-(1,3-benzodioxol-5-yloxy)ethyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 329977-37-9 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-2-naphthalenyl)oxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 329977-41-5 CAPLUS

CN 1-Piperidineethanol, .alpha.-[(1,3-benzodioxol-5-yloxy)methyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 329977-42-6 CAPLUS


CN 1-Piperidineethanol, .alpha.-[(1,3-benzodioxol-5-yloxy)methyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 329977-43-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[2-[ (7-methoxy-2-naphthalenyl)oxy]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 329977-45-9 CAPLUS

CN 1-Piperidineethanol, .alpha.-[[[(2,3-dihydro-1,4-benzodioxin-5-yl)oxy]methyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)- (9CI) (CA INDEX NAME)



RN 329977-46-0 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-[3-[(2,3-dihydro-1,4-benzodioxin-5-yl)oxy]propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329977-47-1 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[2-[3-[(2,3-dihydro-1,4-benzodioxin-5-yl)oxy]ethyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329977-48-2 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[(1-naphthalenyloxy)methyl]- (9CI) (CA INDEX NAME)



RN 329977-49-3 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1-naphthoxyloxy)propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329977-53-9 CAPLUS

CN 9H-Carbazole, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 329977-54-0 CAPLUS


CN 9H-Carbazole, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 329977-56-2 CAPLUS

09/712,129


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[2-(2-methoxyphenoxy)ethyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329977-57-3 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[2-(1-methylethoxy)phenoxy]methyl- (9CI) (CA INDEX NAME)



RN 329977-58-4 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[2-(1-methylethoxy)phenoxy]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329977-59-5 CAPLUS



CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[2-[2-(1-methylethoxy)phenoxy]ethyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329977-60-8 CAPLUS


CN 1-Piperidineethanol, .alpha.-[[ (4-chloro-1-naphthalenyl)oxy]methyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329977-61-9 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-[ (4-chloro-1-naphthalenyl)oxy]propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329977-62-0 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[2-[(4-chloro-1-naphthalenyl)oxy]ethyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329977-63-1 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[(4-methoxy-1-naphthalenyl)oxy]methyl- (9CI) (CA INDEX NAME)



RN 329977-64-2 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(4-methoxy-1-naphthalenyl)oxy]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329977-65-3 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[2-[(4-methoxy-1-naphthalenyl)oxy]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 329977-66-4 CAPLUS


1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[(7-fluoro-1-naphthalenyl)oxy]methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329977-67-5 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(7-fluoro-1-naphthalenyl)oxy]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329977-68-6 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[2-[ (7-fluoro-1-naphthalenyl)oxy]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 329977-69-7 CAPLUS


CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[[ (7-methoxy-1-naphthalenyl)oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329977-70-0 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[7-methoxy-1-naphthalenyl]oxy]propyl]-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 329977-71-1 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[2-[7-methoxy-1-naphthalenyl]oxy]ethyl]-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329977-72-2 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1-naphthalenyloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 5

RE

- (1) Hoechst Roussel Pharma; EP 0402644 A 1990 CAPLUS
- (2) Hoechst Roussel Pharma; WO 9511680 A 1995 CAPLUS
- (3) Novonordisk As; WO 9427998 A 1994 CAPLUS
- (4) Sacristan, A; WO 9632389 A 1996 CAPLUS
- (5) Strupczewski, J; JOURNAL OF MEDICINAL CHEMISTRY 1995, V38(7), P1119 CAPLUS

11 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 2000:725447 CAPLUS

DN 133:301178

TI Use of CYP2D6 inhibitors in combination therapies  
 IN Obach, Ronald Scott  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 18 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

NO US

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059486	A2	20001012	WO 2000-IB304	20000320
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-128136 P 19990407


AB This invention relates to the use of a CYP2D6 inhibitor in combination with a drug having CYP2D6-catalyzed metab., wherein the drug and the CYP2D6 inhibitor are not the same compd.; and pharmaceutical compns. for said use.

IT 133454-47-4, Iloperidone

RL: BAC (Biological activity or effector, except adverse); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (use of CYP2D6 inhibitors in combination therapies)

RN 133454-47-4 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



09/712,129

~~ANSWER 6 OF 24 CAPLUS COPYRIGHT 2001 ACS~~

~~AN 2000:277835 CAPLUS~~

~~DN 132:298845~~

~~TI Therapy for improving cognition~~

~~IN De Nijs, Paul Leonce Irma; Parys, Wim Louis Julien~~

~~PA Janssen Pharmaceutica N.V., Belg.~~

~~SO PCT Int. Appl., 7 pp.~~

~~CODEN: PIXXD2~~


~~DT Patent~~

~~LA English~~

~~FAN.CNT 1~~

rgs

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000023057	A2	20000427	WO 1999-EP7804	19991012
	WO 2000023057	A3	20000727		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9964727	A1	20000508	AU 1999-64727	19991012
	BR 9914419	A	20010626	BR 1999-14419	19991012
	EP 1121131	A2	20010808	EP 1999-952580	19991012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2001001403	A	20010320	NO 2001-1403	20010320
PRAI	EP 1998-203454	A	19981016		
	WO 1999-EP7804	W	19991012		
AB	The present invention is concerned with pharmaceutical compns. comprising a carrier and as first active ingredient an atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor (II), each in an amt. producing a therapeutically beneficial effect in patients suffering from psychosis, or Alzheimer's disease or related dementias. The therapeutically beneficial effect can be a synergistic effect on the cognitive functioning of patients suffering from Alzheimer's disease or related dementias or the prevention of the further deterioration of cognition in the patients, or the redn. of adverse effects assocd. with one of the active ingredients by the other of the active ingredients. Preferred compns. comprise risperidone as the atypical antipsychotic and galantamine as the acetylcholinesterase inhibitor.				
IT	<b>133454-47-4, Iloperidone</b> RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutics for improving cognition contg. antipsychotic agent and acetylcholinesterase inhibitor)				
RN	133454-47-4 CAPLUS				
CN	Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)				



09/712,129

ANSWER 7 OF 24 CAPLUS COPYRIGHT 2001 ACS  
2000:199317 CAPLUS  
132:236993

TI Preparation of cinnamamides and 3-phenylpropionamides as 5-HT1A receptor antagonists and their use as quick-acting antidepressants  
IN Kuroita, Takanobu; Bogauchi, Masahiro; Nishiyama, Akira; Morio, Yasunori  
PA Yoshitomi Pharmaceutical Industries, Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 79 pp.

CODEN: JKXXAF


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000086603	A2	20000328	JP 1999-199662	19990713
PRAI	JP 1998-199934		19980715		
OS	MARPAT 132:236993				

GI



AB The amides I [X = H, OH, C1-8 alkoxy, halo; R1 = substituted cycloalkylamino, alkylamino, piperidino, piperazino, etc.; R3 = H, C1-18 alkyl, halo; R4 = (alkyl)amino, pyrrolidino, morpholino, etc.; Ra, Rb, Rc = H, alkyl(oxy), OH, halo, acyl, etc.; RaRb, RbRc may form (CH2)4, CH:CHCH:CH] are prepd. 3-[2-(2,3-Epoxypropan-1-yloxy)phenyl]propionamide was refluxed with 4-benzylpiperidine in EtOH to give an oily product, which was treated with p-toluenesulfonic acid to afford 2-H2NCO(CH2)2C6H4OCH2CH(OH)CH2Z tosylate (Z = 4-benzylpiperidino).

IT 262271-61-4P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5-HT1A receptor antagonists as quick-acting antidepressants)

RN 262271-61-4 CAPLUS

CN Pyrrolidine, 1-[3-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-hydroxypropoxy]phenyl]-1-oxo-2-propenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

09/712,129



● HCl

09/712,129

ANSWER 8 OF 24 CAPLUS COPYRIGHT 2001 ACS  
1999:451295 CAPLUS  
131:73642

TI Preparation of 7-[(piperidin-1-yl)propoxy]chromen-4-one derivatives useful in the treatment of psychosis, schizophrenia and allergy

IN Foguet, Rafael; Bolos, Jordi; Sacristan, Aurelio; Castello, Josep M.; Ortiz, Jose A.

PA Ferrer Internacional, S.A., Spain

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9935144	A1	19990715	WO 1998-EP8497	19981229
	W: AU, BR, CA, CZ, IL, JP, KR, MX, NO, NZ, PL, RO, RU, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ES 2144355	A1	20000601	ES 1997-2718	19971230
	ES 2144355	B1	20010101		
	AU 9925143	A1	19990726	AU 1999-25143	19981229
	EP 970076	A1	20000112	EP 1998-966856	19981229
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
	BR 9807276	A	20000502	BR 1998-7276	19981229
	JP 2001515517	T2	20010918	JP 1999-535630	19981229
	NO 9904161	A	19991025	NO 1999-4161	19990827
	US 6187793	B1	20010213	US 1999-380092	19991221
PRAI	ES 1997-2718	A	19971230		
	WO 1998-EP8497	W	19981229		

OS MARPAT 131:73642

GI




AB 7-[3-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]propoxy]chromen-4-one derivs. I (R = H, CHO, CH<sub>2</sub>OR<sub>2</sub>, COOH; R1 = H, CH<sub>2</sub>OH; R2 = alkyl and one of the substituents R and R1 should be H) were prep'd. The compds. are new and are useful in the treatment of psychosis, schizophrenia and allergy. The affinity of I for D<sub>2</sub>, 5-HT<sub>2A</sub>, and histamine H<sub>1</sub> receptors was detd.

IT 229030-72-2P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);  
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of [(piperidinyl)propoxy]chromenones and their affinity for D2,  
 5-HT2A, and histamine H1 receptors)

RN 229030-72-2 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)




IT 220077-15-6P 220077-17-8P 220077-19-0P

220077-20-3P 229030-73-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of [(piperidinyl)propoxy]chromenones and their affinity for D2,  
 5-HT2A, and histamine H1 receptors)

RN 220077-15-6 CAPLUS


CN 4H-1-Benzopyran-3-carboxylic acid, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 220077-17-8 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-(hydroxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 220077-19-0 CAPLUS  
CN 4H-1-Benzopyran-3-carboxaldehyde, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-oxo- (9CI) (CA INDEX NAME)




RN 220077-20-3 CAPLUS  
CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methoxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 229030-73-3 CAPLUS  
CN 4H-1-Benzopyran-3-carboxylic acid, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-oxo- (9CI) (CA INDEX NAME)




IT 183849-43-6

RL: RCT (Reactant)

(prepn. of [(piperidinyl)propoxy]chromenones and their affinity for D2,  
5-HT2A, and histamine H1 receptors)

RN 183849-43-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-  
piperidinyl]propoxy]-3-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RE.CNT 2


RE

(1) Ferrer; ES 9600323 A 1996

(2) Ferrer; WO 9632389 A 1996 CAPLUS

L17 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:355752 CAPLUS  
 DN 131:719  
 TI A covalent conjugate of clozapine with a fatty acid and its use for  
 treating schizophrenia  
 IN Bradley, Matthews O.; Shashoua, Victor E.; Swindell, Charles S.; Webb,  
 Nigel L.  
 PA Neuromedica, Inc., USA  
 SO PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926661	A1	19990603	WO 1998-US24412	19981116
	W: AU, CA, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6197764	B1	20010306	US 1997-978541	19971126
	AU 9914115	A1	19990615	AU 1999-14115	19981116
	EP 1044023	A1	20001018	EP 1998-957987	19981116
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE				
	JP 2001523732	T2	20011127	JP 2000-521862	19981116
PRAI	US 1997-978541	A	19971126		
	WO 1998-US24412	W	19981116		
AB	The invention provides compns. that include conjugates of a fatty acid mol., preferably cis-docosahexaenoic acid, and clozapine. The conjugates are useful in treating psychol. disorders such as schizophrenia. Docosahexaenoic acid-clozapine (prepn. given) was at least six times longer-acting than clozapine against locomotor behavioral arousal in rats treated with R(-) apomorphine.				
IT	133454-47-4, Iloperidone				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical further contg.; clozapine conjugate with fatty acid for treating schizophrenia)				
RN	133454-47-4 CAPLUS				
CN	Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)				



RE.CNT 4

RE

- (1) Marder, S; Journal of Clinical Psychiatry 1996, V57(Suppl 03), P9
- (2) Scotia Holdings PLC; EP 0599576 A 1994 CAPLUS
- (3) Shashoua, V; US 4939174 A 1990 CAPLUS
- (4) Stowell, M; WO 9817325 A 1998

D7 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:297269 CAPLUS  
 DN 130:332902  
 TI Treatment of schizophrenia with AMPAkines and neuroleptics  
 IN Johnson, Steven A.; Rogers, Gary A.; Lynch, Gary S.  
 PA Cortex Pharmaceuticals, Inc., USA; The Regents of the University of California  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921422	A1	19990506	WO 1998-US22707	19981026
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU	9913658	A1	19990517	AU 1999-13658	19981026
EP	1026950	A1	20000816	EP 1998-957382	19981026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR	9814106	A	20001003	BR 1998-14106	19981026
US	6166008	A	20001226	US 1998-179341	19981026
JP	2001520978	T2	20011106	JP 2000-517599	19981026
PRAI	US 1997-63627	P	19971027		
	WO 1998-US22707	W	19981026		

OS MARPAT 130:332902

AB The invention relates to treatment of schizophrenia and related psychotic disorders, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. In a particular aspect, the invention relates to methods for the use of AMPA receptor up-modulators in conjunction with antipsychotics for the treatment of schizophrenia. Kits contg. the compns. in appropriate form for administration are also provided. A representative AMPAkine (CX516) synergistically enhanced clozapine antagonism of methamphetamine-induced rearing activity.


IT 133454-47-4, Iloperidone

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (AMPAkines and antipsychotic agents for treatment of schizophrenia)

RN 133454-47-4 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)

not claimed



RE.CNT 2

RE

(1) The Regents Of The University Of California; WO 9707799 A1 1997 CAPLUS  
(2) Vanover, K; Eur J Pharmacol 1997, V332(2), P115 CAPLUS



Reserve  
15824

L17 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:487828 CAPLUS  
 DN 129:122674  
 TI 3-(Heteroaryl)-1-[(2,3-dihydro-1H-isoindol-2-yl)alkyl]pyrrolidines and  
 3-(heteroaryl)-1-[(2,3-dihydro-1H-indol-1-yl)alkyl]pyrrolidines and  
 related compounds and their use as analgesics and antipsychotics  
 IN Strupczewski, Joseph T.; Helsley, Grover C.; Glamkowski, Edward J.;  
 Chiang, Yulin; Bordeau, Kenneth J.; Nemoto, Peter A.; Tegeler, John J.  
 PA Hoechst Marion Roussel, Inc., USA  
 SO U.S., 78 pp. Cont.-in-part of U.S. Ser. No. 144,265, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5776963	A	19980707	US 1994-329000	19941025
	ZA 9003830	A	19910227	ZA 1990-3830	19900518
	US 5364866	A	19941115	US 1992-969383	19921030
	IL 103622	A1	20001206	IL 1992-103622	19921103
	CA 2175212	AA	19950504	CA 1994-2175212	19941027
	WO 9511680	A1	19950504	WO 1994-US12054	19941027
			W: AU, CA, CN, CZ, JP, KR, NO, NZ, PL, RO, RU		
			RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE		
AU	9481228	A1	19950522	AU 1994-81228	19941027
EP	730452	A1	19960911	EP 1995-900390	19941027
			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE		
CN	1136275	A	19961120	CN 1994-194302	19941027
JP	09511215	T2	19971111	JP 1994-512724	19941027
PL	181059	B1	20010531	PL 1994-314135	19941027
ZA	9408501	A	19960528	ZA 1994-8501	19941028
ZA	9500423	A	19960528	ZA 1995-423	19941028
ZA	9502653	A	19960528	ZA 1995-2653	19941028
US	5550130	A	19960827	US 1995-465697	19950606
US	5552414	A	19960903	US 1995-466246	19950606
US	5554614	A	19960910	US 1995-467173	19950606
US	5556858	A	19960917	US 1995-467387	19950606
US	5559117	A	19960924	US 1995-466726	19950606
US	5559116	A	19960924	US 1995-469521	19950606
US	5559126	A	19960924	US 1995-471237	19950606
US	5561128	A	19961001	US 1995-469883	19950606
US	5569653	A	19961029	US 1995-471775	19950606
US	5571828	A	19961105	US 1995-469361	19950606
US	5571814	A	19961105	US 1995-471574	19950606
US	5574032	A	19961112	US 1995-466765	19950606
US	5578624	A	19961126	US 1995-468076	19950606
US	5578605	A	19961126	US 1995-470437	19950606
US	5580875	A	19961203	US 1995-466960	19950606
US	5580890	A	19961203	US 1995-467794	19950606
US	5580879	A	19961203	US 1995-467796	19950606
US	5580886	A	19961203	US 1995-469884	19950606
US	5580891	A	19961203	US 1995-471236	19950606
US	5580887	A	19961203	US 1995-471753	19950606
US	5583145	A	19961210	US 1995-466895	19950606
US	5589488	A	19961231	US 1995-468074	19950606
US	5589494	A	19961231	US 1995-470040	19950606
US	5589495	A	19961231	US 1995-471515	19950606
US	5591745	A	19970107	US 1995-469365	19950606

09/712,129

US	5593995	A	19970114	US	1995-471514	19950606
US	5597842	A	19970128	US	1995-470438	19950606
US	5599821	A	19970204	US	1995-469357	19950606
US	5607945	A	19970304	US	1995-466821	19950606
US	5612342	A	19970318	US	1995-466252	19950606
US	5612343	A	19970318	US	1995-467912	19950606
US	5614543	A	19970325	US	1995-469000	19950606
US	5614543	B1	19981215			
US	5624927	A	19970429	US	1995-466773	19950606
US	5629326	A	19970513	US	1995-465707	19950606
US	5639764	A	19970617	US	1995-470836	19950606
US	5646161	A	19970708	US	1995-471755	19950606
US	5648363	A	19970715	US	1995-466767	19950606
US	5652241	A	19970729	US	1995-468344	19950606
US	5654319	A	19970805	US	1995-470704	19950606
US	5663449	A	19970902	US	1995-470059	19950606
US	5811435	A	19980922	US	1995-468991	19950606
US	5811430	A	19980922	US	1995-471754	19950606
US	5840727	A	19981124	US	1995-468960	19950606
US	5843977	A	19981201	US	1995-467795	19950606
US	5843949	A	19981201	US	1995-467951	19950606
US	5854263	A	19981229	US	1995-469501	19950606
US	5854243	A	19981229	US	1995-470715	19950606
US	5874435	A	19990223	US	1995-470039	19950606
US	5889035	A	19990330	US	1995-467133	19950606
US	5889004	A	19990330	US	1995-471393	19950606
US	5919798	A	19990706	US	1995-468075	19950606
US	5965546	A	19991012	US	1995-471512	19950606
US	5977140	A	19991102	US	1995-465863	19950606
US	5977113	A	19991102	US	1995-466241	19950606
US	5998417	A	19991207	US	1995-468065	19950606
US	6043240	A	20000328	US	1995-467401	19950606
US	6110938	A	20000829	US	1995-471032	19950606
US	6140345	A	20001031	US	1995-468611	19950606
US	6207680	B1	20010327	US	1995-468993	19950606
US	5571803	A	19961105	US	1995-577325	19951222
US	5637710	A	19970610	US	1995-577151	19951222
NO	9601686	A	19960614	NO	1996-1686	19960426
CZ	288464	B6	20010613	CZ	1996-3628	19961210
US	37029	E	20010123	US	1998-185968	19981105
AU	9897207	A1	19990422	AU	1998-97207	19981218
US	6251907	B1	20010626	US	1999-335271	19990617
PRAI	US 1989-354411	B2	19890519			
	US 1989-456790	B1	19891229			
	US 1990-619825	B1	19901129			
	US 1991-944705	B2	19910905			
	US 1991-788269	B2	19911105			
	US 1992-969383	A2	19921030			
	US 1993-144265	B2	19931028			
	US 1998-354411	B1	19890519			
	US 1994-329000	A	19941025			
	AU 1994-81228	A3	19941027			
	WO 1994-US12054	W	19941027			
	US 1995-468611	A3	19950606			
	US 1995-471574	A5	19950606			
OS	MARPAT 129:122674					
GI						



AB Heteroaryl-substituted piperidines, pyrrolidines, and piperazines, specifically I [Q = N-substituted 3-pyrrolidinyl, 4-piperidinyl, or 1-piperazinyl; X = O, S, NH, NR2; R1 = H, alkyl, OH, Cl, F, Br, iodo, alkoxy, CF3, NO2, amino; R2 = alkyl, aralkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxy carbonyl, phenylsulfonyl; p = 1 or 2], are useful as antipsychotic and analgesic agents. The compds. are esp. useful for treating psychosis, and depot derivs. in particular are useful for providing long-acting effects. For instance, coupling of 3-(1-piperazinyl)-1H-indazole with 1-[4-(3-chloropropoxy)-3-methoxyphenyl]ethanone in DMF contg. K2CO3 and KI at 90.degree. gave title compd. II. In the apomorphine-induced climbing assay in mice, selected I were typically over 8-fold more potent than clozapine. Similarly, 3 compds. I were more potent than propoxyphene and pentazocine in the phenylquinone-induced writhing test in mice.

IT 133454-45-2P 133454-46-3P 133454-47-4P  
 133454-48-5P 133454-50-9P 133454-51-0P  
 133454-52-1P 133454-53-2P 133454-54-3P  
 133454-55-4P 133454-56-5P 133454-58-7P  
 133454-59-8P 133454-60-1P 133454-61-2P  
 133454-62-3P 133454-63-4P 133454-64-5P  
 133454-65-6P 133454-66-7P 133454-67-8P  
 133454-68-9P 133454-69-0P 133454-70-3P  
 133454-71-4P 133454-72-5P 133454-75-8P  
 133454-76-9P 133454-78-1P 133454-79-2P  
 133454-80-5P 133454-81-6P 133454-82-7P  
 133454-83-8P 133454-84-9P 133454-85-0P  
 133454-86-1P 133454-87-2P 133454-88-3P  
 133454-89-4P 133454-90-7P 133454-91-8P  
 133454-92-9P 133454-93-0P 133454-94-1P  
 133454-95-2P 133454-96-3P 133454-97-4P  
 133454-98-5P 133454-99-6P 133455-00-2P  
 133455-01-3P 133455-02-4P 133455-04-6P  
 133455-05-7P 133455-06-8P 133455-07-9P  
 133483-85-9P 151718-66-0P 151718-70-6P  
 151718-72-8P 151718-73-9P 151718-75-1P  
 151718-76-2P 151718-77-3P 151718-78-4P  
 151718-79-5P 151718-80-8P 151718-81-9P


151718-82-0P 151718-83-1P 151718-85-3P  
 151718-86-4P 151718-88-6P 151718-89-7P  
 151719-08-3P 151719-09-4P 151719-10-7P  
 151719-11-8P 151719-12-9P 151719-23-2P  
 151719-24-3P 151719-26-5P 151719-28-7P  
 151719-30-1P 151719-58-3P 151719-59-4P  
 151719-61-8P 151719-63-0P 152018-90-1P  
 152018-92-3P 152019-18-6P 152019-19-7P  
 152019-21-1P 152019-23-3P 162438-80-4P  
 162438-81-5P 167266-39-9P 167266-40-2P  
 170170-47-5P 170170-48-6P 170216-73-6P  
 170216-74-7P 170216-75-8P 170216-76-9P  
 170216-77-0P 170216-78-1P 170217-55-7P  
 170217-68-2P 170217-71-7P 170217-72-8P  
 170217-82-0P 170217-83-1P 170218-77-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroarylpiriperidines, -pyrrolidines, and -piperazines as antipsychotics and analgesics)


RN 133454-45-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-46-3 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-47-4 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-48-5 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-50-9 CAPLUS

CN Ethanone, 1-[4-[2-[4-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-51-0 CAPLUS

CN Ethanone, 1-[4-[2-[4-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-50-9

CMF C23 H26 N2 O4



CM 2

CRN 110-17-8

CMF C4 H4 O4


CDER 2:E

Double bond geometry as shown.



RN 133454-52-1 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-53-2 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-52-1


CMF C24 H30 N4 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-54-3 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-55-4 CAPLUS  
CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 133454-56-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-58-7 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-59-8 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-60-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-61-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-62-3 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-63-4 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-62-3  
CMF C25 H29 Cl N2 O4




CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E


Double bond geometry as shown.



RN 133454-64-5 CAPLUS  
 CN Ethanone, 1-[4-[3-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-65-6 CAPLUS  
 CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 133454-66-7 CAPLUS  
 CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

09/712, 129


CRN 133454-65-6  
CMF C22 H25 F N2 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 133454-67-8 CAPLUS  
CN Methanone, [3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 133454-68-9 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




09/712,129

RN 133454-69-0 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-70-3 CAPLUS  
CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-71-4 CAPLUS  
CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-70-3  
CMF C23 H25 F N2 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 133454-72-5 CAPLUS  
 CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 133454-75-8 CAPLUS  
 CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-74-7  
 CMF C24 H28 F N3 O4




CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E

Double bond geometry as shown.



RN 133454-76-9 CAPLUS  
 CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-78-1 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methylphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-77-0

CMF C24 H27 F N2 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-79-2 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133454-80-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-81-6 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-82-7 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-83-8 CAPLUS  
CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro- (9CI) (CA INDEX NAME)




RN 133454-84-9 CAPLUS

CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-83-8

CMF C30 H31 F N4 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-85-0 CAPLUS

CN Ethanone, 1-[4-[4-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-86-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-87-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-86-1  
CMF C23 H27 N3 O3 S




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-88-3 CAPLUS  
CN Ethanone, 1-[3,5-dibromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133454-89-4 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-90-7 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-(3-phenoxypropyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 133454-91-8 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-92-9 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-93-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 133454-94-1 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-95-2 CAPLUS

CN Methanone, [4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 133454-96-3 CAPLUS

CN Ethanone, 1-[3-bromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-97-4 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-[4-(1-ethoxyethyl)-2-methoxyphenoxy]propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 133454-98-5 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 133454-99-6 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester), (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-98-5

CMF C26 H31 F N2 O5




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E


Double bond geometry as shown.



RN 133455-00-2 CAPLUS


CN 1-Pentanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)

09/712,129



RN 133455-01-3 CAPLUS

CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 133455-02-4 CAPLUS

CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133455-01-3

CMF C22 H26 F N3 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E


Double bond geometry as shown.



RN 133455-04-6 CAPLUS


CN 1-Propanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133455-05-7 CAPLUS

CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 133455-06-8 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 133455-07-9 CAPLUS

CN Ethanone, 1-[3-ethoxy-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




09/712,129


RN 133483-85-9 CAPLUS  
CN Benzonitrile, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 151718-66-0 CAPLUS  
CN Ethanone, 1-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-5-methylphenyl]- (9CI) (CA INDEX NAME)




RN 151718-70-6 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151718-72-8 CAPLUS  
CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 151718-73-9 CAPLUS  
CN Acetamide, N-[5-acetyl-2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 151718-75-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151718-76-2 CAPLUS  
CN Benzenamine, 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 151718-77-3 CAPLUS  
CN Benzenamine, 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperidinyl]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)




RN 151718-78-4 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 151718-79-5 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151718-80-8 CAPLUS

CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 151718-81-9 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, oxime (9CI) (CA INDEX NAME)




RN 151718-82-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 151718-83-1 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, hydrazone (9CI) (CA INDEX NAME)




RN 151718-85-3 CAPLUS

09/712,129

CN Ethanone, 1-[4-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151718-86-4 CAPLUS

CN Ethanone, 1-[4-[(2Z)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151718-88-6 CAPLUS


CN Ethanone, 1-[3-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 151718-89-7 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(5-methoxy-1H-indol-6-yl)oxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-08-3 CAPLUS  
CN Phenol, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-5-(1-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 151719-09-4 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-5-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-10-7 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-4-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-11-8 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-12-9 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 151719-23-2 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-24-3 CAPLUS  
CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 151719-26-5 CAPLUS  
CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 151719-28-7 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-30-1 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-7-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-58-3 CAPLUS

CN Isoquinoline, 5-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 151719-59-4 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-1H-indol-5-yl)oxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




09/712,129

RN 151719-61-8 CAPLUS

CN Ethanone, 1-[4-[(2R)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151719-63-0 CAPLUS

CN Ethanone, 1-[4-[(2S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152018-90-1 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-26-5

CMF C23 H26 F N3 O3




09/712, 129

CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 152018-92-3 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-7-yloxy)propyl]-4-piperidinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 151719-30-1  
CMF C<sub>23</sub> H<sub>24</sub> F N<sub>3</sub> O<sub>2</sub>



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.



RN 152019-18-6 CAPLUS  
CN Isoquinoline, 5-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-


09/712,129

piperidinyl]propoxy]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-58-3

CMF C24 H24 F N3 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 152019-19-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-1H-indol-5-yl)oxy]propyl]-4-piperidinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-59-4

CMF C24 H26 F N3 O3




09/712,129

CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 152019-21-1 CAPLUS  
CN Ethanone, 1-[4-[(2R)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-61-8  
CMF C25 H29 F N2 O4  
CDES 1:R


Absolute stereochemistry.



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 152019-23-3 CAPLUS  
CN Ethanone, 1-[4-[(2S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

09/712, 129

CM 1

CRN 151719-63-0  
CMF C25 H29 F N2 O4  
CDES 1:S


Absolute stereochemistry.




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 162438-80-4 CAPLUS  
CN Ethanone, 1-[3-(dimethylamino)-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 162438-81-5 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 167266-39-9 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 167266-40-2 CAPLUS


CN Ethanone, 1-[3-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenoxy]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 170170-47-5 CAPLUS


CN Benzenemethanol, 4-[(3-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy]-2-hydroxy-5-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 170170-48-6 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 170216-73-6 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 170216-74-7 CAPLUS  
CN Acetamide, N-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 170216-75-8 CAPLUS  
CN 1,2-Benzisoxazole, 3-[1-[3-(3-ethyl-4-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 170216-76-9 CAPLUS

CN 1,2-Benzisoxazole, 3-[1-[3-(3-ethyl-4-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 170216-77-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133455-06-8

CMF C24 H28 F N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 170216-78-1 CAPLUS

CN 2(1H)-Naphthalenone, 6-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 170217-55-7 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[(4-methoxyphenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 170217-68-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-hydroxypropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 170217-71-7 CAPLUS

CN Decanoic acid, 2-(4-acetyl-2-methoxyphenoxy)-1-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]methyl ester (9CI) (CA INDEX NAME)



RN 170217-72-8 CAPLUS


09/712,129

CN Decanoic acid, 2-(4-acetyl-2-methoxyphenoxy)-1-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)methyl]ethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 170217-71-7

CMF C34 H45 F N2 O6




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.



RN 170217-82-0 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-(2,5-dimethoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 170217-83-1 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-(2,5-dimethoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 170218-77-6 CAPLUS  
 CN 1H-Indazole-1-carboxylic acid, 3-[1-(phenoxy carbonyl)-4-piperidinyl]-, phenyl ester (9CI) (CA INDEX NAME)



IT 170218-95-8  
 RL: RCT (Reactant)  
 (prepn. of heteroaryl piperidines, -pyrrolidines, and -piperazines as antipsychotics and analgesics)  
 RN 170218-95-8 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-(1-benzoyl-6-fluoro-1H-indazol-3-yl)-, phenyl ester (9CI) (CA INDEX NAME)




IT 151718-71-7P 170170-52-2P 170218-96-9P  
 170218-99-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of heteroaryl piperidines, -pyrrolidines, and -piperazines as antipsychotics and analgesics)  
 RN 151718-71-7 CAPLUS  
 CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 170170-52-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-hydroxy-5-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 170218-96-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1-benzoyl-6-fluoro-1H-indazol-3-yl)-, phenyl ester, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 170218-95-8

CMF C26 H22 F N3 O3




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



RN 170218-99-2 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[1-(phenylsulfonyl)-1H-indazol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)



09/712,129

LIW ANSWER 12 OF 24 CAPLUS COPYRIGHT 2001 ACS  
AN 1996:724186 CAPLUS  
DN 126:8109  
TI Preparation and formulation of [(benzisoxazolylpiperidino)propoxy]chromeno  
nes as antipsychotics and anxiolytics  
IN Foguet, Rafael; Anglada, Lluis; Bolos, Jordi; Ortiz, Jose A.; Sacristan,  
Aurelio; Castello, Josep M.  
PA Ferrer Internacional, S.A., Spain  
SO PCT Int. Appl., 23 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9632389	A1	19961017	WO 1996-EP1551	19960411
	W: AU, CA, JP, KR, NO, NZ, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ES 2101646	A1	19970701	ES 1995-737	19950412
	ES 2101646	B1	19980401		
	ES 2103237	A1	19970901	ES 1996-323	19960209
	ES 2103237	B1	19980616		
	IL 117646	A1	20000601	IL 1996-117646	19960325
	ZA 9602391	A	19970312	ZA 1996-2391	19960326
	CA 2192596	AA	19961017	CA 1996-2192596	19960411
	AU 9655004	A1	19961030	AU 1996-55004	19960411
	AU 696494	B2	19980910		
	EP 765323	A1	19970402	EP 1996-912012	19960411
	EP 765323	B1	20010711		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 10501557	T2	19980210	JP 1996-530716	19960411
	AT 203022	E	20010715	AT 1996-912012	19960411
	NO 9605300	A	19961211	NO 1996-5300	19961211
	US 5736558	A	19980407	US 1997-750790	19970314
PRAI	ES 1995-737	A	19950412		
	ES 1996-323	A	19960209		
	WO 1996-EP1551	W	19960411		
OS	MARPAT	126:8109			
GI					



AB Title compds. [I; R1 = 3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy] [II; R = H or (hydroxy)alkyl] were prep'd. Thus, I [R = CH2OH, R1 = O(CH2)3Cl] was aminated by 4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine to give II (R = CH2OH) which had ID50 of 0.4mg/kg orally against apomorphine-induced climbing in mice.  
IT 183849-40-3P 183849-41-4P 183849-43-6P


**183849-44-7P 183849-45-8P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and formulation of [(benzisoxazolylpiperidino)propoxy]chromenones as antipsychotics and anxiolytics)


RN 183849-40-3 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 183849-41-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methyl- (9CI) (CA INDEX NAME)




RN 183849-43-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 183849-44-7 CAPLUS


CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183849-45-8 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(hydroxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

X17 ANSWER 13 OF 24 CAPIUS COPYRIGHT 2001 ACS  
AN 1996:705556 CAPLUS  
DN 125:317375  
TI Serotonin-2/dopamine-2 receptor-blocking agents for treating mental  
disorders associated with cerebrovascular disorders  
IN Otomo, Eiichi  
PA Sumitomo Pharmaceuticals Company, Limited, Japan  
SC Can. Pat. Appl., 19 pp.  
CODEN: CPXXEB  
DT Patent  
LA English  
FAN CNT 1


US  
ABN

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	CA 2167004	AA	19960713	CA 1996-2167004	19960111
	JP 08193033	A2	19960730	JP 1995-3191	19950112
	JP 2001316264	A2	20011113	JP 2001-135136	19950112
	EP 730865	A1	19960911	EP 1996-100360	19960111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE					
CN 1142945		A	19970219	CN 1996-101615	19960112

AB The present invention provides an agent for treating mental disorders assoc'd. with cerebrovascular disorders. The agents are compds. which can block both serotonin-2 and dopamine-2 receptors, e.g. SM-9018. Prepn. of SM-9018 [N-(4-(4-(1,2-benzoisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cis-cyclohexanddicarboxyimide hydrochloride] is described, as are capsule and tablet formulations contg. it, and results of a clin. trial employing it.

IT 133454-47-4, HP 873  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Serotonin-2/dopamine-2 receptor-blocking agents for treating mental  
disorders, including schizophrenia, depression, and anxiety disorders)


RN 133454-47-4 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



applicants

L17 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 AN 1995:913283 CAPLUS  
 DN 123:314016  
 TI Preparation of heteroarylpiperidines, -pyrrolidines, and -piperazines as antipsychotics and analgesics  
 IN Strupczewski, Joseph; Helsley, Grover C.; Glamkowski, Edward J.; Chiang, Yulin; Bordeau, Kenneth J.; Nemoto, Peter A.; Tegeler, John J.  
 PA Hoechst-Roussel Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 296 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511680	A1	19950504	WO 1994-US12054	19941027
	W: AU, CA, CN, CZ, JP, KR, NO, NZ, PL, RO, RU RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5776963	A	19980707	US 1994-329000	19941025
	AU 9481228	A1	19950522	AU 1994-81228	19941027
	EP 730452	A1	19960911	EP 1995-900390	19941027
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09511215	T2	19971111	JP 1994-512724	19941027
	PL 181059	B1	20010531	PL 1994-314135	19941027
	ZA 9408501	A	19960528	ZA 1994-8501	19941028
	ZA 9500423	A	19960528	ZA 1995-423	19941028
	ZA 9502653	A	19960528	ZA 1995-2653	19941028
	NO 9601686	A	19960614	NO 1996-1686	19960426
PRAI	US 1993-144265	A	19931028		
	US 1994-329000	A	19941025		
	US 1989-354411	B2	19890519		
	US 1989-456790	B1	19891229		
	US 1990-619825	B1	19901129		
	US 1991-944705	B2	19910905		
	US 1991-700269	B2	19911105		
	US 1992-969383	A2	19921030		
	WO 1994-US12054	W	19941027		
OS	MARPAT	123:314016			
GI					



**AB** Title compds. [I; R = heterocyclyl group Q; X = O, S, (un)substituted NH; Y = H, halo, alkyl, alkoxy, etc.; Y2 = heterocyclloxyalkyl, (hetero)aryloxyalkyl, etc.; N = O and Z = CH; n = 1 and Z = CH or N; p = 1 or 2] were prep'd. Thus, 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole was N-alkylated by 3,4-(MeO)(MeOC)C6H3(CH2)3Cl to give title compd. II which had ED50 of 0.095mg/kg i.p. for inhibition of apomorphine-induced climbing in mice.

**IT**

133454-45-2P 133454-46-3P 133454-47-4P  
 133454-48-5P 133454-50-9P 133454-51-0P  
 133454-52-1P 133454-53-2P 133454-54-3P  
 133454-55-4P 133454-56-5P 133454-58-7P  
 133454-59-8P 133454-60-1P 133454-61-2P  
 133454-62-3P 133454-63-4P 133454-64-5P  
 133454-65-6P 133454-66-7P 133454-67-8P  
 133454-68-9P 133454-69-0P 133454-70-3P  
 133454-71-4P 133454-72-5P 133454-75-8P  
 133454-76-9P 133454-78-1P 133454-79-2P  
 133454-80-5P 133454-81-6P 133454-82-7P  
 133454-83-8P 133454-84-9P 133454-85-0P  
 133454-86-1P 133454-87-2P 133454-88-3P  
 133454-89-4P 133454-90-7P 133454-91-8P  
 133454-92-9P 133454-93-0P 133454-94-1P  
 133454-95-2P 133454-96-3P 133454-97-4P  
 133454-98-5P 133454-99-6P 133455-00-2P  
 133455-01-3P 133455-02-4P 133455-04-6P  
 133455-05-7P 133455-06-8P 133455-07-9P  
 133483-85-9P 151718-66-0P 151718-70-6P  
 151718-72-8P 151718-73-9P 151718-75-1P  
 151718-76-2P 151718-77-3P 151718-78-4P  
 151718-79-5P 151718-80-8P 151718-81-9P  
 151718-82-0P 151718-83-1P 151718-85-3P  
 151718-86-4P 151718-88-6P 151718-89-7P  
 151719-08-3P 151719-09-4P 151719-10-7P  
 151719-11-8P 151719-12-9P 151719-23-2P  
 151719-24-3P 151719-26-5P 151719-28-7P  
 151719-30-1P 151719-58-3P 151719-59-4P  
 151719-61-8P 151719-63-0P 152018-90-1P


152018-92-3P 152019-18-6P 152019-19-7P  
 152019-21-1P 152019-23-3P 162438-80-4P  
 162438-81-5P 167266-39-9P 167266-40-2P  
 170170-47-5P 170170-48-6P 170216-73-6P  
 170216-74-7P 170216-75-8P 170216-76-9P  
 170216-77-0P 170216-78-1P 170217-55-7P  
 170217-68-2P 170217-71-7P 170217-72-8P  
 170217-82-0P 170217-83-1P 170218-77-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroarylpiriperidines, -pyrrolidines, and -piperazines as antipsychotics and analgesics)


RN 133454-45-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-46-3 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-47-4 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



09/712,129


RN 133454-48-5 CAPLUS

CN Ethanone, 1-[4-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-50-9 CAPLUS

CN Ethanone, 1-[4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-51-0 CAPLUS

CN Ethanone, 1-[4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-50-9

CMF C23 H26 N2 O4



CM 2


CRN 110-17-8

CMF C4 H4 O4

CDES 2:E


09/712,129

Double bond geometry as shown.



RN 133454-52-1 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-53-2 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-52-1

CMF C24 H30 N4 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E


Double bond geometry as shown.



RN 133454-54-3 CAPLUS


CN Ethanone, 1-[4-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-55-4 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 133454-56-5 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-58-7 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-59-8 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-60-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-61-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-62-3 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-63-4 CAPLUS

CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-62-3

CMF C25 H29 Cl N2 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-64-5 CAPLUS

CN Ethanone, 1-[4-[3-[4-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-65-6 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 133454-66-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-65-6

CMF C22 H25 F N2 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-67-8 CAPLUS

CN Methanone, [3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 133454-68-9 CAPLUS

CN Ethanone, 1-[4-[4-(4-(1H-indazol-3-yl)-1-piperidinyl)butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-69-0 CAPLUS

CN Ethanone, 1-[4-[2-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-70-3 CAPLUS

CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxyl]phenyl]- (9CI) (CA INDEX NAME)



09/712,129


RN 133454-71-4 CAPLUS

CN Ethanone, 1-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-70-3

CMF C23 H25 F N2 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.



RN 133454-72-5 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 133454-75-8 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-74-7


CMF C24 H28 F N3 O4




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 133454-76-9 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-78-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methylphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-77-0  
CMF C24 H27 F N2 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-79-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-80-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-81-6 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-82-7 CAPLUS

CN Ethanone, 1-[4-[4-[6-fluoro-1H-indazol-3-yl]-1-piperidinyl]butoxy]-3-methoxyphenyl- (9CI) (CA INDEX NAME)



RN 133454-83-8 CAPLUS

CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro- (9CI) (CA INDEX NAME)




RN 133454-84-9 CAPLUS

CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-83-8


CMF C30 H31 F N4 O4




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 133454-85-0 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-86-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-87-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-86-1

CMF C23 H27 N3 O3 S




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-88-3 CAPLUS

CN Ethanone, 1-[3,5-dibromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133454-89-4 CAPLUS

CN Ethanone, 1-[4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-90-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-(3-phenoxypropyl)-4-piperidinyl]- (9CI)  
(CA INDEX NAME)




RN 133454-91-8 CAPLUS

CN Ethanone, 1-[4-[2-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-92-9 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-93-0 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperidinyl]propoxy]-3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 133454-94-1 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-95-2 CAPLUS

CN Methanone, [4-[3-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)



RN 133454-96-3 CAPLUS


CN Ethanone, 1-[3-bromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



09/712,129

RN 133454-97-4 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-[4-(1-ethoxyethyl)-2-methoxyphenoxy]propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 133454-98-5 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 133454-99-6 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester), (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-98-5

CMF C26 H31 F N2 O5




CM 2


09/712,129

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 133455-00-2 CAPLUS  
CN 1-Pentanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133455-01-3 CAPLUS  
CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 133455-02-4 CAPLUS  
CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133455-01-3  
CMF C22 H26 F N3 O2




CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E


Double bond geometry as shown.




RN 133455-04-6 CAPLUS  
 CN 1-Propanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133455-05-7 CAPLUS  
 CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 133455-06-8 CAPLUS  
 CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 133455-07-9 CAPLUS

CN Ethanone, 1-[3-ethoxy-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133483-85-9 CAPLUS

CN Benzonitrile, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 151718-66-0 CAPLUS

CN Ethanone, 1-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-5-methylphenyl]- (9CI) (CA INDEX NAME)



RN 151718-70-6 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151718-72-8 CAPLUS


CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 151718-73-9 CAPLUS

CN Acetamide, N-[5-acetyl-2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 151718-75-1 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151718-76-2 CAPLUS  
CN Benzenamine, 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 151718-77-3 CAPLUS  
CN Benzenamine, 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 151718-78-4 CAPLUS  
CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151718-79-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151718-80-8 CAPLUS

CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 151718-81-9 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, oxime (9CI) (CA INDEX NAME)




RN 151718-82-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 151718-83-1 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, hydrazone (9CI) (CA INDEX NAME)



RN 151718-85-3 CAPLUS

CN Ethanone, 1-[4-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151718-86-4 CAPLUS

CN Ethanone, 1-[4-[(2Z)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151718-88-6 CAPLUS


CN Ethanone, 1-[3-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 151718-89-7 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(5-methoxy-1H-indol-6-yl)oxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 151719-08-3 CAPLUS


CN Phenol, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-5-

(1-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 151719-09-4 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-5-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 151719-10-7 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-4-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 151719-11-8 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-

piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-12-9 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 151719-23-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-24-3 CAPLUS

CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 151719-26-5 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 151719-28-7 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-30-1 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-7-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-58-3 CAPLUS

CN Isoquinoline, 5-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 151719-59-4 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-1H-indol-5-yl)oxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 151719-61-8 CAPLUS

CN Ethanone, 1-[4-[(2R)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151719-63-0 CAPLUS

CN Ethanone, 1-[4-[(2S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152018-90-1 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-26-5

CMF C23 H26 F N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 152018-92-3 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-7-yloxy)propyl]-4-piperidinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-30-1


CMF C23 H24 F N3 O2



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 152019-18-6 CAPLUS

CN Isoquinoline, 5-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-58-3  
CMF C24 H24 F N3 O2



CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 152019-19-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-1H-indol-5-yl)oxy]propyl]-4-piperidinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-59-4

CMF C24 H26 F N3 O3



CM 2


CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

09/712,129

Double bond geometry as shown.



RN 152019-21-1 CAPLUS

CN Ethanone, 1-[4-[(2R)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 151719-61-8

CMF C25 H29 F N2 O4

CDES 1:R

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 152019-23-3 CAPLUS

CN Ethanone, 1-[4-[(2S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 151719-63-0

CMF C25 H29 F N2 O4

CDES 1:S


Absolute stereochemistry.




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 162438-80-4 CAPLUS  
CN Ethanone, 1-[3-(dimethylamino)-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 162438-81-5 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 167266-39-9 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 167266-40-2 CAPLUS


CN Ethanone, 1-[3-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 170170-47-5 CAPLUS


CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-hydroxy-5-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 170170-48-6 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 170216-73-6 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 170216-74-7 CAPLUS  
CN Acetamide, N-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 170216-75-8 CAPLUS  
CN 1,2-Benzisoxazole, 3-[1-[3-(3-ethyl-4-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 170216-76-9 CAPLUS

CN 1,2-Benzisoxazole, 3-[1-[3-(3-ethyl-4-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 170216-77-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133455-06-8

CMF C24 H28 F N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 170216-78-1 CAPLUS

CN 2(1H)-Naphthalenone, 6-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 170217-55-7 CAPLUS

CN 1-Piperidineethanol, 4-(6-fluoro-1,2-benzisoxazol-3-yl)-.alpha.-[(4-methoxyphenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 170217-68-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-hydroxypropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 170217-71-7 CAPLUS

CN Decanoic acid, 2-(4-acetyl-2-methoxyphenoxy)-1-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]methyl]ethyl ester (9CI) (CA INDEX NAME)



RN 170217-72-8 CAPLUS


09/712,129

CN Decanoic acid, 2-(4-acetyl-2-methoxyphenoxy)-1-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)methyl]ethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 170217-71-7


CMF C34 H45 F N2 O6



CM 2


CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.



RN 170217-82-0 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-(2,5-dimethoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 170217-83-1 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-(2,5-dimethoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 170218-77-6 CAPLUS  
CN 1H-Indazole-1-carboxylic acid, 3-[1-(phenoxy carbonyl)-4-piperidinyl]-, phenyl ester (9CI) (CA INDEX NAME)



IT 170218-95-8  
RL: RCT (Reactant)  
(prepn. of heteroaryl piperidines, -pyrrolidines, and -piperazines as antipsychotics and analgesics)  
RN 170218-95-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-(1-benzoyl-6-fluoro-1H-indazol-3-yl)-, phenyl ester (9CI) (CA INDEX NAME)




IT 151718-71-7P 170170-52-2P 170218-96-9P  
170218-99-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of heteroaryl piperidines, -pyrrolidines, and -piperazines as antipsychotics and analgesics)  
RN 151718-71-7 CAPLUS  
CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 170170-52-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-hydroxy-5-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 170218-96-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1-benzoyl-6-fluoro-1H-indazol-3-yl)-, phenyl ester, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 170218-95-8

CMF C26 H22 F N3 O3




CM 2

CRN 110-16-7


CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.



RN 170218-99-2 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[1-(phenylsulfonyl)-1H-indazol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 AN 1995:772587 CAPLUS  
 DN 123:169657  
 TI Preparation of heteroarylpiperidines, -pyrrolidines and -piperazines as  
 antipsychotics and analgesics.  
 IN Strupczewski, Joseph T.; Helsley, Grover C.; Chiang, Yulin; Bordeau,  
 Kenneth J.; Glamkowski, Edward J.  
 PA Hoechst-Roussel Pharmaceuticals, Inc., USA  
 SO U.S., 61 pp. Cont.-in-part of U.S. Ser. No.788,269, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5364866	A	19941115	US 1992-969383	19921030
	ZA 9003830	A	19910227	ZA 1990-3830	19900518
	IL 103622	A1	20001206	IL 1992-103622	19921103
	WO 9309102	A1	19930513	WO 1992-US9276	19921104
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9230570	A1	19930607	AU 1992-30570	19921104
	AU 674499	B2	19970102		
	EP 612318	A1	19940831	EP 1992-924151	19921104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	HU 70855	A2	19951128	HU 1994-1316	19921104
	RU 2127731	C1	19990320	RU 1994-28105	19921104
	RO 114447	B1	19990430	RO 1994-761	19921104
	PL 176230	B1	19990531	PL 1992-303452	19921104
	EP 959076	A1	19991124	EP 1999-111017	19921104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	EP 959075	A1	19991124	EP 1999-111314	19921104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	CZ 287611	B6	20010117	CZ 1994-1102	19921104
	EP 1110954	A1	20010627	EP 2001-102643	19921104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	EP 542136	A1	19930519	EP 1992-118982	19921105
	R: PT				
	EP 957102	A1	19991117	EP 1999-111016	19921105
	R: PT				
	EP 963984	A1	19991215	EP 1999-111315	19921105
	R: PT				
	EP 1052255	A1	20001115	EP 2000-115401	19921105
	R: PT				
	NO 9401647	A	19940504	NO 1994-1647	19940504
	FI 9402052	A	19940630	FI 1994-2052	19940504
	US 5658911	A	19970819	US 1994-309395	19940920
	US 5776963	A	19980707	US 1994-329000	19941025
	US 5550130	A	19960827	US 1995-465697	19950606
	US 5552414	A	19960903	US 1995-466246	19950606
	US 5554614	A	19960910	US 1995-467173	19950606
	US 5556858	A	19960917	US 1995-467387	19950606
	US 5559117	A	19960924	US 1995-466726	19950606
	US 5559116	A	19960924	US 1995-469521	19950606
	US 5559126	A	19960924	US 1995-471237	19950606
	US 5561128	A	19961001	US 1995-469883	19950606

US 5569653	A	19961029	US 1995-471775	19950606
US 5571828	A	19961105	US 1995-469361	19950606
US 5571814	A	19961105	US 1995-471574	19950606
US 5574032	A	19961112	US 1995-466765	19950606
US 5578624	A	19961126	US 1995-468076	19950606
US 5578605	A	19961126	US 1995-470437	19950606
US 5580875	A	19961203	US 1995-466960	19950606
US 5580890	A	19961203	US 1995-467794	19950606
US 5580879	A	19961203	US 1995-467796	19950606
US 5580886	A	19961203	US 1995-469884	19950606
US 5580891	A	19961203	US 1995-471236	19950606
US 5580887	A	19961203	US 1995-471753	19950606
US 5583145	A	19961210	US 1995-466895	19950606
US 5589488	A	19961231	US 1995-468074	19950606
US 5589494	A	19961231	US 1995-470040	19950606
US 5589495	A	19961231	US 1995-471515	19950606
US 5591745	A	19970107	US 1995-469365	19950606
US 5593995	A	19970114	US 1995-471514	19950606
US 5597842	A	19970128	US 1995-470438	19950606
US 5599821	A	19970204	US 1995-469357	19950606
US 5607945	A	19970304	US 1995-466821	19950606
US 5612342	A	19970318	US 1995-466252	19950606
US 5612343	A	19970318	US 1995-467912	19950606
US 5614543	A	19970325	US 1995-469000	19950606
US 5614543	B1	19981215		
US 5624927	A	19970429	US 1995-466773	19950606
US 5629326	A	19970513	US 1995-465707	19950606
US 5639764	A	19970617	US 1995-470836	19950606
US 5646161	A	19970708	US 1995-471755	19950606
US 5648363	A	19970715	US 1995-466767	19950606
US 5652241	A	19970729	US 1995-468344	19950606
US 5654319	A	19970805	US 1995-470704	19950606
US 5663449	A	19970902	US 1995-470059	19950606
US 5811435	A	19980922	US 1995-468991	19950606
US 5811430	A	19980922	US 1995-471754	19950606
US 5840727	A	19981124	US 1995-468960	19950606
US 5843977	A	19981201	US 1995-467795	19950606
US 5843949	A	19981201	US 1995-467951	19950606
US 5854263	A	19981229	US 1995-469501	19950606
US 5854243	A	19981229	US 1995-470715	19950606
US 5874435	A	19990223	US 1995-470039	19950606
US 5889035	A	19990330	US 1995-467133	19950606
US 5889004	A	19990330	US 1995-471393	19950606
US 5919798	A	19990706	US 1995-468075	19950606
US 5965546	A	19991012	US 1995-471512	19950606
US 5977140	A	19991102	US 1995-465863	19950606
US 5977113	A	19991102	US 1995-466241	19950606
US 5998417	A	19991207	US 1995-468065	19950606
US 6043240	A	20000328	US 1995-467401	19950606
US 6110938	A	20000829	US 1995-471032	19950606
US 6140345	A	20001031	US 1995-468611	19950606
US 6207680	B1	20010327	US 1995-468993	19950606
US 5571803	A	19961105	US 1995-577325	19951222
US 5637710	A	19970610	US 1995-577151	19951222
CZ 288464	B6	20010613	CZ 1996-3628	19961210
AU 9717754	A1	19970605	AU 1997-17754	19970402
AU 709451	B2	19990826		
US 37029	E	20010123	US 1998-185968	19981105

PRAI	US 1989-354411	B2	19890519
	US 1989-456790	B1	19891229
	US 1990-619825	B1	19901129
	US 1991-944705	B2	19910905
	US 1991-788269	B2	19911105
	US 1998-354411	B1	19890519
	US 1992-969383	A	19921030
	CS 1994-1102	A	19921104
	EP 1992-924151	A3	19921104
	WO 1992-US9276	A	19921104
	EP 1992-118982	A3	19921105
	US 1993-144265	B2	19931028
	US 1994-329000	A3	19941025
	US 1995-471574	A5	19950606

OS MARPAT 123:169657

GI



AB Title compds. [I; X = O, S, NH, NR2; R2 = alkyl, aryl, aralkyl, cycloalkyl, aroyl, alkanoyl, PhSO2; p = 1, 2; Y = H, alkyl, OH, Cl, F, Br, iodo, alkoxy, CF3, NO2, amino, OH, alkoxy; Q = Q1, Q2; Z = CH, N; Y2 = Q3, Q4, etc.; X1 = (CH2)n, CH2C.tplbond.CCH2, CH2CH:CHCH2, etc.; n = 2-5; R = H, alkyl, alkoxy OH, CO2H, Cl, F, Br, iodo, amino, dialkylamino, NO2, alkylthio, F3CO, aminocarbonyl, CHO, etc.; R3 = H, OMe; m = 1-3], were prep'd. Thus, 3-(1-piperazinyl)-1H-indazole (prepn. given), K2CO3, 1-[4-(3-chloropropoxy)-3-methoxyphenyl]ethanone, and KI were stirred 5 h in DMF to give 64% 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]ethanone. In the apomorphine-induced climbing assay in rats, I showed ED50 = 0.095-22.6 mg/kg, i.p.; I inhibited phenylquinone-induced writhing in mice with ED50 = 0.03-0.17 mg/kg s.c.

IT 133454-45-2P 133454-46-3P 133454-47-4P  
 133454-48-5P 133454-49-6P 133454-50-9P  
 133454-51-0P 133454-53-2P 133454-54-3P  
 133454-56-5P 133454-58-7P 133454-59-8P  
 133454-60-1P 133454-61-2P 133454-62-3P  
 133454-63-4P 133454-64-5P 133454-65-6P  
 133454-66-7P 133454-67-8P 133454-68-9P  
 133454-69-0P 133454-70-3P 133454-71-4P  
 133454-72-5P 133454-74-7P 133454-75-8P


133454-76-9P 133454-77-0P 133454-78-1P  
 133454-79-2P 133454-80-5P 133454-82-7P  
 133454-84-9P 133454-85-0P 133454-87-2P  
 133454-88-3P 133454-89-4P 133454-90-7P  
 133454-91-8P 133454-92-9P 133454-93-0P  
 133454-94-1P 133454-95-2P 133454-96-3P  
 133454-97-4P 133454-98-5P 133454-99-6P  
 133455-00-2P 133455-01-3P 133455-02-4P  
 133455-03-5P 133455-04-6P 133455-05-7P  
 133455-06-8P 133455-07-9P 133483-85-9P  
 151718-66-0P 151718-68-2P 151718-70-6P  
 151718-72-8P 151718-73-9P 151718-74-0P  
 151718-75-1P 151718-76-2P 151718-77-3P  
 151718-78-4P 151718-79-5P 151718-80-8P  
 151718-81-9P 151718-82-0P 151718-83-1P  
 151718-85-3P 151718-86-4P 151718-87-5P  
 151718-88-6P 151718-89-7P 151719-09-4P  
 151719-10-7P 151719-11-8P 151719-12-9P  
 151719-22-1P 151719-23-2P 151719-24-3P  
 151719-26-5P 151719-27-6P 151719-28-7P  
 151719-58-3P 151719-59-4P 151719-61-8P  
 151719-63-0P 152018-90-1P 152018-91-2P  
 152018-92-3P 152019-18-6P 152019-19-7P  
 152019-21-1P 152019-23-3P 162438-80-4P  
 162438-81-5P 162438-82-6P 162438-83-7P  
**167266-39-9P 167266-40-2P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroarylpiridines, -pyrrolidines and -piperazines as antipsychotics and analgesics)


RN 133454-45-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-46-3 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-47-4 CAPLUS

CN Ethanone, 1-[4-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-48-5 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-49-6 CAPLUS


CN Ethanone, 1-[4-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-50-9 CAPLUS

CN Ethanone, 1-[4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-

methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-51-0 CAPLUS

CN Ethanone, 1-[4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-50-9

CMF C23 H26 N2 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 133454-53-2 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-52-1


CMF C24 H30 N4 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-54-3 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-56-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-58-7 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-59-8 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-60-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-61-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-62-3 CAPLUS

CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-63-4 CAPLUS

CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-62-3

CMF C25 H29 Cl N2 O4




CM 2

CRN 110-17-8


CMF C4 H4 O4

CDES 2:E


Double bond geometry as shown.



RN 133454-64-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-65-6 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 133454-66-7 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-65-6  
CMF C22 H25 F N2 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


09/712,129

Double bond geometry as shown.




RN 133454-67-8 CAPLUS

CN Methanone, [3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 133454-68-9 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-69-0 CAPLUS

CN Ethanone, 1-[4-[2-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-70-3 CAPLUS

CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133454-71-4 CAPLUS

CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-70-3

CMF C23 H25 F N2 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-72-5 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 133454-74-7 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-75-8 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-74-7

CMF C24 H28 F N3 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-76-9 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-77-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxol-3-yl)-1-piperidinyl]propoxy]-3-methylphenyl]- (9CI) (CA INDEX NAME)




RN 133454-78-1 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxol-3-yl)-1-piperidinyl]propoxy]-3-methylphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-77-0

CMF C24 H27 F N2 O3




CM 2

CRN 110-17-8


CMF C4 H4 O4

CDES 2:E


Double bond geometry as shown.




RN 133454-79-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-80-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-82-7 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-84-9 CAPLUS  
CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-83-8  
CMF C30 H31 F N4 O4




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 133454-85-0 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-87-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-86-1  
CMF C23 H27 N3 O3 S




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-88-3 CAPLUS  
CN Ethanone, 1-[3,5-dibromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133454-89-4 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-90-7 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-(3-phenoxypropyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 133454-91-8 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-92-9 CAPLUS  
CN Ethanone, 2,2,2-trifluoro-1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-93-0 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 133454-94-1 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]butoxy]-3-

methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-95-2 CAPLUS

CN Methanone, [4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 133454-96-3 CAPLUS

CN Ethanone, 1-[3-bromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-97-4 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-[4-(1-ethoxyethyl)-2-methoxyphenoxy]propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 133454-98-5 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 133454-99-6 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester), (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-98-5

CMF C26 H31 F N2 O5



CM 2


CRN 110-17-8

CMF C4 H4 O4

CDES 2:E


09/712,129

Double bond geometry as shown.




RN 133455-00-2 CAPLUS

CN 1-Pentanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133455-01-3 CAPLUS

CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 133455-02-4 CAPLUS

CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133455-01-3

CMF C22 H26 F N3 O2




CM 2

CRN 110-17-8


09/712,129

CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133455-03-5 CAPLUS  
CN 1,2-Benzisoxazole, 3-[1-[3-(4-bromo-2-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 133455-04-6 CAPLUS  
CN 1-Propanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133455-05-7 CAPLUS  
CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 133455-06-8 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 133455-07-9 CAPLUS

CN Ethanone, 1-[3-ethoxy-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133483-85-9 CAPLUS

CN Benzonitrile, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 151718-66-0 CAPLUS

CN Ethanone, 1-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-5-methylphenyl]- (9CI) (CA INDEX NAME)




RN 151718-68-2 CAPLUS

CN Acetamide, N-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-


09/712,129

piperidinylpropoxyphenyl]- (9CI) (CA INDEX NAME)



RN 151718-70-6 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151718-72-8 CAPLUS

CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 151718-73-9 CAPLUS


CN Acetamide, N-[5-acetyl-2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)

09/712,129



RN 151718-74-0 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-(4-ethyl-3-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151718-75-1 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)



RN 151718-76-2 CAPLUS


CN Benzenamine, 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 151718-77-3 CAPLUS


CN Benzenamine, 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperidinyl]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)




RN 151718-78-4 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 151718-79-5 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151718-80-8 CAPLUS

CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 151718-81-9 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, oxime (9CI) (CA INDEX NAME)




RN 151718-82-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 151718-83-1 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, hydrazone (9CI) (CA INDEX NAME)




RN 151718-85-3 CAPLUS

09/712,129

CN Ethanone, 1-[4-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151718-86-4 CAPLUS

CN Ethanone, 1-[4-[(2Z)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151718-87-5 CAPLUS

CN Ethanone, 1-[3-[(4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-4-hydroxyphenyl]-, monohydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 151718-88-6 CAPLUS

09/712,129


CN Ethanone, 1-[3-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenoxy]-4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 151718-89-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(5-methoxy-1H-indol-6-yl)oxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 151719-09-4 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-5-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



09/712,129


RN 151719-10-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-4-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-11-8 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 151719-12-9 CAPLUS


CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 151719-22-1 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-[4-(1-ethoxyethyl)-2-methoxyphenoxy]propyl]-4-

piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 151719-23-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-24-3 CAPLUS

CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 151719-26-5 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 151719-27-6 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 151719-28-7 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-58-3 CAPLUS

CN Isoquinoline, 5-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 151719-59-4 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-1H-indol-5-yl)oxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 151719-61-8 CAPLUS

CN Ethanone, 1-[4-[(2R)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151719-63-0 CAPLUS

CN Ethanone, 1-[4-[(2S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152018-90-1 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

09/712,129


CRN 151719-26-5  
CMF C23 H26 F N3 O3



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 152018-91-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 151719-27-6  
CMF C24 H28 F N3 O2 S



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 152018-92-3 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-7-yloxy)propyl]-4-piperidinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-30-1

CMF C23 H24 F N3 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 152019-18-6 CAPLUS

CN Isoquinoline, 5-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-58-3

CMF C24 H24 F N3 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 152019-19-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-1H-indol-5-yl)oxy]propyl]-4-piperidinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-59-4

CMF C24 H26 F N3 O3



CM 2


CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

09/712,129

Double bond geometry as shown.



RN 152019-21-1 CAPLUS

CN Ethanone, 1-[4-[(2R)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 151719-61-8

CMF C25 H29 F N2 O4

CDES 1:R

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 152019-23-3 CAPLUS

CN Ethanone, 1-[4-[(2S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 151719-63-0

CMF C25 H29 F N2 O4

CDES 1:S


Absolute stereochemistry.




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 162438-80-4 CAPLUS  
CN Ethanone, 1-[3-(dimethylamino)-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 162438-81-5 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]propyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 162438-82-6 CAPLUS

CN 1,2-Benzisoxazole, 3-[1-[3-(4-ethyl-2-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 162438-83-7 CAPLUS

CN 1(2H)-Naphthalenone, 6-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 167266-39-9 CAPLUS


CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 167266-40-2 CAPLUS

CN Ethanone, 1-[3-[(2E)-4-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)-2-butenyl]oxy]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 151719-08-3P

RL: BYP (Byproduct); PREP (Preparation)  
(prepn. of heteroaryl piperidines, -pyrrolidines and -piperazines as  
antipsychotics and analgesics)

RN 151719-08-3 CAPLUS

CN Phenol, 2-[(3-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy]-5-(1-methoxyethyl)- (9CI) (CA INDEX NAME)




IT 133454-55-4 133454-57-6

RL: RCT (Reactant)  
(prepn. of heteroaryl piperidines, -pyrrolidines and -piperazines as  
antipsychotics and analgesics)


RN 133454-55-4 CAPLUS

CN Benzenemethanol, 4-[(3-[(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 133454-57-6 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




IT 151718-71-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of heteroarylpiperidines, -pyrrolidines and -piperazines as  
antipsychotics and analgesics)

RN 151718-71-7 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



09/712,129

117 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2001 ACS

AN 1995:652268 CAPLUS

DN 123:55888

TI Preparation of psoralen derivatives as drugs

IN Hansen, John Bondo; Groenvald, Frederik Christian

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 37 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9427998	A1	19941208	WO 1994-DK200	19940525
	W: AU, BG, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LV, NO, NZ, PL, RO, RU, SK, UA, US, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU	9469240	A1	19941220	AU 1994-69240	19940525
EP	700398	A1	19960313	EP 1994-917565	19940525
EP	700398	B1	19971126		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP	08510264	T2	19961029	JP 1994-500124	19940525
AT	160567	E	19971215	AT 1994-917565	19940525
FI	9505680	A	19951124	FI 1995-5680	19951124
NO	9504764	A	19960125	NO 1995-4764	19951124
PRAI	DK 1993-607		19930526		
	WO 1994-DK200		19940525		
OS	MARPAT	123:55888			
GI					



I



Q =

AB Title compds. [I; A is hydrocarbon contg. 2-6 C-atoms; R1 is (un)substituted benzoyl, (un)substituted heterocyclyl; R2 = (un)substituted Q] and their pharmaceutically acceptable salts, useful in the treatment of indications related to the CNS-system, cardiovascular system or gastrointestinal disorders (no data), are prepd. Thus, 1-(2-chlorophenyl)piperazine was reacted with 9-(3-bromopropoxy)psoralen in acetone contg. K<sub>2</sub>CO<sub>3</sub> under reflux for 16 h followed by treatment with HCl to give the title compd. 9-[3-[4-(2-chlorophenyl)piperazin-1-yl]propoxy]psoralen hydrochloride. General procedures for testing the title compds. but without specific data are described. Pharmaceutical compns. contg. I are described.

IT 164387-42-2P 164387-50-2P 164387-56-8P

164387-58-0P 164387-59-1P 164387-60-4P

164387-65-9P

09/712,129

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of psoralen derivs. as drugs)


RN 164387-42-2 CAPLUS

CN 7H-Furo[3,2-g][1]benzopyran-7-one, 9-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 164387-41-1


CMF C26 H23 F N2 O5



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 164387-50-2 CAPLUS

CN 7H-Furo[3,2-g][1]benzopyran-7-one, 9-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-, ethanedioate (9CI) (CA INDEX NAME)

CM 1


CRN 164387-49-9

CMF C27 H25 F N2 O5



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 164387-56-8 CAPLUS  
CN 7H-Furo[3,2-g][1]benzopyran-7-one, 9-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-, ethanedioate (9CI) (CA INDEX NAME)


CM 1

CRN 164387-55-7  
CMF C25 H21 F N2 O5



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 164387-58-0 CAPLUS  
CN 7H-Furo[3,2-g][1]benzopyran-7-one, 9-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethoxy]-, ethanedioate (9CI) (CA INDEX NAME)


CM 1

CRN 164387-57-9  
CMF C24 H21 N3 O4 S




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 164387-59-1 CAPLUS  
CN 7H-Furo[3,2-g][1]benzopyran-7-one, 4-chloro-9-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 164387-60-4 CAPLUS


CN 7H-Furo[3,2-g][1]benzopyran-7-one, 4-bromo-9-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 164387-65-9 CAPLUS

CN 7H-Furo[3,2-g][1]benzopyran-7-one, 9-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]propoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

09/712,129



●2 HCl.


09/12/12, 129

117 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2001 ACS  
AN 1994:106994 CAPLUS  
DN 120:106994  
TI Preparation of heteroaryl-8-azabicyclo(3.2.1)octanes as antipsychotic agents, 5-HT3 receptor antagonists and inhibitors of the reuptake of serotonin  
IN Glamkowski, Edward J.; Fink, David M.; Kurys, Barbara E.; Chiang, Yulin  
PA Hoechst-Roussel Pharmaceuticals Inc., USA  
SO U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 650,144, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5234931	A	19930810	US 1992-831027	19920204
	FI 9200435	A	19920805	FI 1992-435	19920131
	CA 2060573	AA	19920805	CA 1992-2060573	19920203
	NO 9200438	A	19920805	NO 1992-438	19920203
	AU 9210605	A1	19920806	AU 1992-10605	19920203
	AU 641842	B2	19930930		
	HU 60494	A2	19920928	HU 1992-321	19920203
	HU 207863	B	19930628		
	ZA 9200753	A	19921028	ZA 1992-753	19920203
	JP 05059049	A2	19930309	JP 1992-17668	19920203
	JP 08009613	B4	19960131		
	HU 62295	A2	19930428	HU 1992-3977	19920203
	HU 217616	B	20000328		
	PL 169092	B1	19960531	PL 1992-293363	19920203
	AT 138377	E	19960615	AT 1992-101706	19920203
	ES 2089255	T3	19961001	ES 1992-101706	19920203
	IL 100861	A1	19970218	IL 1992-100861	19920203
	RU 2075479	C1	19970320	RU 1992-5010691	19920203
	CZ 284754	B6	19990217	CZ 1992-297	19920203
	US 5334599	A	19940802	US 1993-37134	19930325
	US 5340936	A	19940823	US 1993-37047	19930325
PRAI	US 1991-650144	B2	19910204		
	HU 1992-321	A3	19920203		
	US 1992-831027	A3	19920204		

OS MARPAT 120:106994

GI




I

AB Title compds. I (X = O, S; Y = H, halo, alkoxy; p, m = 1,2; n = 2-4; R = H, halo, alkyl, alkoxy, HO, halo, H2N, alkylamino, O2N, alkylthio, F3CO, NC, F3C, alkylcarbonyl, (substituted) arylcarbonyl) or a salt, geometric


or optical isomers thereof, showing the effects described in the title, are prep'd. Di-Et 1-(2-fluorophenyl)-1-methoxymethanephosphonate (prepn. given) in THF was treated with BuLi and tropinone to give (2-fluorophenyl)(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)methanone-HCl which was converted in 4 steps to give I (X = O, Rm = 3,4-(MeO)Ac, Yp = H, n = 4).HCl (II). In an assay for potential antidepressant activity which block serotonin uptake the IC50 of II was 0.027 .mu.M.

IT 144062-09-9P 144062-10-2P 144062-11-3P  
 144062-12-4P 144062-13-5P 144062-14-6P  
 144062-15-7P 144062-16-8P 144062-17-9P  
 144062-18-0P 144062-19-1P 144062-20-4P  
 144062-21-5P 144062-22-6P 144062-23-7P  
 144253-62-3P 144253-63-4P 144253-64-5P  
 144253-65-6P 144253-66-7P 144253-67-8P  
 144253-68-9P 144253-69-0P 144253-70-3P  
 144253-71-4P 152535-40-5P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of, as drug)

RN 144062-09-9 CAPPLUS  
 CN Ethanone, 1-[4-[4-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-10-2 CAPPLUS  
 CN Ethanone, 1-[4-[3-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-11-3 CAPLUS

CN Ethanone, 1-[4-[3-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-12-4 CAPLUS

CN Ethanone, 1-[4-[2-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-13-5 CAPLUS

CN Ethanone, 1-[4-[2-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-14-6 CAPLUS

CN Ethanone, 1-[4-[4-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-15-7 CAPLUS

CN Ethanone, 1-[4-[3-[3-(1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-16-8 CAPIUS

CN Ethanone, 1-[4-[2-[3-(1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-17-9 CAPIUS

CN Ethanone, 1-[4-[4-[3-(1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-18-0 CAPLUS

CN Ethanone, 1-[4-[2-[3-(6-fluoro-1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-19-1 CAPLUS

CN Ethanone, 1-[4-[4-[3-(6-fluoro-1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-20-4 CAPLUS

CN Ethanone, 1-[4-[3-[3-(6-fluoro-1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-21-5 CAPLUS

CN Ethanone, 1-[4-[2-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-22-6 CAPLUS

CN Ethanone, 1-[4-[3-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-23-7 CAPLUS

CN Ethanone, 1-[4-[4-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




09/712,129

RN 144253-62-3 CAPLUS  
CN Ethanone, 1-[4-[4-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 144253-63-4 CAPLUS  
CN Ethanone, 1-[4-[3-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 144253-64-5 CAPLUS  
CN Ethanone, 1-[4-[3-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144062-11-3  
CMF C26 H30 N2 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 144253-65-6 CAPLUS

CN Ethanone, 1-[4-[2-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144062-12-4


CMF C25 H27 F N2 O4



CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E


Double bond geometry as shown.



RN 144253-66-7 CAPLUS  
 CN Ethanone, 1-[4-[2-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 144062-13-5  
 CMF C25 H28 N2 O4



CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E

Double bond geometry as shown.




RN 144253-67-8 CAPLUS  
 CN Ethanone, 1-[4-[4-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

09/712,129

CM 1


CRN 144062-14-6  
CMF C27 H31 F N2 O4



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 144253-68-9 CAPLUS  
CN Ethanone, 1-[4-[4-[3-(1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144062-17-9  
CMF C27 H33 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 144253-69-0 CAPLUS

CN Ethanone, 1-[4-[2-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144062-21-5

CMF C25 H28 N2 O3 S




09/712,129

CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 144253-70-3 CAPLUS  
CN Ethanone, 1-[4-[3-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 144062-22-6  
CMF C26 H30 N2 O3 S




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 144253-71-4 CAPLUS  
CN Ethanone, 1-[4-[4-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 152535-40-5 CAPLUS

CN Ethanone, 1-[4-[3-[3-(6-fluoro-1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 AN 1994:54553 CAPLUS  
 DN 120:54553  
 TI Preparation of heteroaryl piperidines, pyrrolidines and piperazines and  
 their use as antipsychotics and analgetics  
 IN Strupczewski, Joseph T.; Helsley, Grover C.; Chiang, Yulin; Bordeau,  
 Kenneth J.; Glamkowski, Edward J.  
 PA Hoechst-Roussel Pharmaceuticals Inc., USA  
 SO Eur. Pat. Appl., 197 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 542136 R: PT US 5364866 IL 103622 EP 957102 R: PT EP 963934 R: PT EP 1052255 R: PT	A1 A A1 A1 A1 A1 A1 A1 A1	19930519 19941115 20001206 19991117 19991215 20001115 20001115 20001115	EP 1992-118982 US 1992-969383 IL 1992-103622 EP 1999-111016 EP 1999-111315 EP 2000-115401	19921105 19921030 19921103 19921105 19921105 19921105
PRAI	US 1991-788269 US 1992-969383 US 1989-354411 US 1989-156790 US 1990-619825 US 1991-944705 EP 1992-118982	A A B2 B1 B1 B2 A3	19911105 19921030 19890519 19891229 19901129 19910905 19921105		
OS	MARPAT 120:54553				
GI					



AB Title compds. I (X = O, S, NH, R2N wherein R2 = alkyl, arylalkyl, aryl, cycloalkyl, aroyl, alkanoyl, PhSO2; Y = H, alkyl, HO, halo, alkoxy, F3C, O2N, H2N; p = 1, 2; Q = substituted piperidinyl, -piperazinyl, -heterocyclyl, etc.), geometrical optical and stereoisomers, or a salt


thereof, are prep'd. 6-Fluoro-3-(4-piperidinyl)-1,2-benzoxazole-HCl, 1-(4-(3-chloropropoxy)-3-methoxyphenyl)ethanone, and DMF were heated at 90.degree. for 16 h to give the title compd. II. The antipsychotic activity in the climbing mice assay for II was ED50 0.095 mg/kg i.p. and the analgesic activity as shown by inhibition of phenylquinone induced-writhing was ED50 0.03 mg/kg 5.0. A large no. of I was prep'd.

IT 151719-93-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, on prepn. of analgesics and antipsychotics)

RN 151719-93-6 CAPLUS

CN Benzenemethanol, 3-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



IT 133454-45-2P 133454-46-3P 133454-47-4P  
 133454-48-5P 133454-49-6P 133454-50-9P  
 133454-51-0P 133454-52-1P 133454-53-2P  
 133454-54-3P 133454-55-4P 133454-56-5P  
 133454-57-6P 133454-58-7P 133454-59-8P  
 133454-60-1P 133454-61-2P 133454-62-3P  
 133454-63-4P 133454-64-5P 133454-65-6P  
 133454-66-7P 133454-67-8P 133454-68-9P  
 133454-69-0P 133454-70-3P 133454-71-4P  
 133454-72-5P 133454-74-7P 133454-75-8P  
 133454-76-9P 133454-77-0P 133454-78-1P  
 133454-79-2P 133454-80-5P 133454-81-6P  
 133454-82-7P 133454-83-8P 133454-84-9P  
 133454-85-0P 133454-86-1P 133454-87-2P  
 133454-88-3P 133454-89-4P 133454-91-8P  
 133454-92-9P 133454-93-0P 133454-94-1P  
 133454-95-2P 133454-96-3P 133454-97-4P  
 133454-98-5P 133454-99-6P 133455-00-2P  
 133455-01-3P 133455-02-4P 133455-04-6P  
 133455-05-7P 133455-06-8P 133455-07-9P  
 133483-85-9P 151718-66-0P 151718-68-2P  
 151718-69-3P 151718-70-6P 151718-71-7P  
 151718-72-8P 151718-73-9P 151718-74-0P  
 151718-75-1P 151718-76-2P 151718-77-3P  
 151718-78-4P 151718-79-5P 151718-80-8P  
 151718-81-9P 151718-82-0P 151718-83-1P  
 151718-85-3P 151718-86-4P 151718-87-5P  
 151718-88-6P 151718-89-7P 151718-93-3P  
 151719-08-3P 151719-09-4P 151719-10-7P  
 151719-11-8P 151719-12-9P 151719-21-0P  
 151719-22-1P 151719-23-2P 151719-24-3P  
 151719-25-4P 151719-26-5P 151719-27-6P  
 151719-28-7P 151719-30-1P 151719-58-3P  
 151719-59-4P 151719-61-8P 151719-63-0P

152018-90-1P 152018-91-2P 152018-92-3P


152019-18-6P 152019-19-7P 152019-21-1P

152019-23-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as analgesic and antipsychotic)


RN 133454-45-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-46-3 CAPLUS

CN Ethanone, 1-[4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-47-4 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-48-5 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-49-6 CAPLUS

CN Ethanone, 1-[4-[4-(4-acetyl-3-methoxyphenyl)butoxy]-3-methoxyphenyl]-1-piperidinyl (9CI) (CA INDEX NAME)



RN 133454-50-9 CAPLUS

CN Ethanone, 1-[4-[2-[4-(4-acetyl-3-methoxyphenyl)ethoxy]-3-methoxyphenyl]-1-piperidinyl]ethane (9CI) (CA INDEX NAME)




RN 133454-51-0 CAPLUS

CN Ethanone, 1-[4-[2-[4-(4-acetyl-3-methoxyphenyl)ethoxy]-3-methoxyphenyl]-1-piperidinyl]ethane (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-50-9


CMF C23 H26 N2 O4




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 133454-52-1 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-53-2 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-52-1  
CMF C24 H30 N4 O3




CM 2

CRN 110-17-8  
CMF C<sub>4</sub> H<sub>4</sub> O<sub>4</sub>  
CDES 2:E


Double bond geometry as shown.




RN 133454-54-3 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl] - (9CI) (CA INDEX NAME)



RN 133454-55-4 CAPLUS  
CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 133454-56-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl] - (9CI) (CA INDEX NAME)




RN 133454-57-6 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-58-7 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-59-8 CAPLUS

CN Ethanone, 1-[4-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




09/712,129


RN 133454-60-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-61-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-62-3 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-63-4 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-62-3  
CMF C25 H29 Cl N2 O4


09/712,129




CM 2

CRN 110-17-8  
CMF C<sub>4</sub> H<sub>4</sub> O<sub>4</sub>  
CDES 2:E


Double bond geometry as shown.



RN 133454-64-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-65-6 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 133454-66-7 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-65-6

09/712,129


CMF C22 H25 F N2 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 133454-67-8 CAPLUS  
CN Methanone, [3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 133454-68-9 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-69-0 CAPLUS


09/712,129

CN Ethanone, 1-[4-[2-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-70-3 CAPLUS

CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133454-71-4 CAPLUS

CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-70-3

CMF C23 H25 F N2 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-72-5 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 133454-74-7 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-75-8 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-74-7

CMF C24 H28 F N3 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-76-9 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-77-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methylphenyl]- (9CI) (CA INDEX NAME)




RN 133454-78-1 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methylphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-77-0

CMF C24 H27 F N2 O3




09/712,129


CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-79-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-80-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-81-6 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-82-7 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]butoxy]-3-

methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-83-8 CAPLUS

CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro- (9CI) (CA INDEX NAME)




RN 133454-84-9 CAPLUS

CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-83-8

CMF C30 H31 F N4 O4




09/712,129


CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 133454-85-0 CAPLUS  
CN Ethanone, 1-[4-[4-[6-chloro-1H-indazol-3-yl]-1-piperazinyl]butoxy]-3-methoxyphenyl- (9CI) (CA INDEX NAME)




RN 133454-86-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl- (9CI) (CA INDEX NAME)



RN 133454-87-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl- (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-86-1  
CMF C23 H27 N3 O3 S




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-88-3 CAPLUS  
CN Ethanone, 1-[3,5-dibromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-89-4 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-91-8 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-92-9 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-93-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 133454-94-1 CAPLUS


CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-95-2 CAPLUS


09/712,129

CN Methanone, [4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 133454-96-3 CAPLUS

CN Ethanone, 1-[3-bromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-97-4 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-[4-(1-ethoxyethyl)-2-methoxyphenoxy]propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 133454-98-5 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 133454-99-6 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester), (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-98-5

CMF C26 H31 F N2 O5




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133455-00-2 CAPLUS

CN 1-Pentanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133455-01-3 CAPLUS  
 CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 133455-02-4 CAPLUS  
 CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133455-01-3  
 CMF C22 H26 F N3 O2



CM 2


CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E

Double bond geometry as shown.




RN 133455-04-6 CAPLUS  
 CN 1-Propanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133455-05-7 CAPLUS

CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 133455-06-8 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 133455-07-9 CAPLUS


CN Ethanone, 1-[3-ethoxy-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



09/712,129


RN 133483-85-9 CAPLUS

CN Benzonitrile, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 151718-66-0 CAPLUS

CN Ethanone, 1-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-5-methylphenyl]- (9CI) (CA INDEX NAME)




RN 151718-68-2 CAPLUS

CN Acetamide, N-[2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 151718-69-3 CAPLUS

CN Ethanone, 1-[4'-(dimethylamino)-6-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 151718-70-6 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151718-71-7 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 151718-72-8 CAPLUS


CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 151718-73-9 CAPLUS

CN Acetamide, N-[5-acetyl-2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 151718-74-0 CAPLUS


CN 1,2-Benzisoxazole, 3-[1-[3-(4-ethyl-3-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151718-75-1 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151718-76-2 CAPLUS  
CN Benzenamine, 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 151718-77-3 CAPLUS  
CN Benzenamine, 3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 151718-78-4 CAPLUS  
CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151718-79-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151718-80-8 CAPLUS

CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 151718-81-9 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, oxime (9CI) (CA INDEX NAME)




RN 151718-82-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 151718-83-1 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-, hydrazone (9CI) (CA INDEX NAME)



RN 151718-85-3 CAPLUS

CN Ethanone, 1-[4-[(2E)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151718-86-4 CAPLUS

CN Ethanone, 1-[4-[(2Z)-4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151718-87-5 CAPLUS

CN Ethanone, 1-[3-[(4-[(6-fluorobenzisoxazol-3-yl)propyl]piperidinyl)butenyl]oxy]-4-hydroxyphenyl-, monohydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 151718-88-6 CAPLUS


CN Ethanone, 1-[3-[(2E)-4-[(4-[(6-fluorobenzisoxazol-3-yl)propyl]butenyl)oxy]-4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 151718-89-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[(1-[(3-[(5-methoxy-1H-indol-6-yl)oxy]propyl)4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151718-93-3 CAPLUS

CN 1(2H)-Naphthalenone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 151719-08-3 CAPLUS

CN Phenol, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-5-(1-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 151719-09-4 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-5-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-10-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-4-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-11-8 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-12-9 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 151719-21-0 CAPLUS


CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151719-22-1 CAPLUS

CN 1,2-Benzisoxazole, 3-[1-[3-[4-(1-ethoxyethyl)-2-methoxyphenoxy]propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 151719-23-2 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-24-3 CAPLUS  
CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 151719-25-4 CAPLUS  
CN 1,2-Benzisoxazole, 3-[1-[3-(4-ethyl-3-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 151719-26-5 CAPLUS  
CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 151719-27-6 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 151719-28-7 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 151719-30-1 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-7-yloxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-58-3 CAPLUS

CN Isoquinoline, 5-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 151719-59-4 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-1H-indol-5-yl)oxy]propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 151719-61-8 CAPLUS  
CN Ethanone, 1-[4-[(2R)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 151719-63-0 CAPLUS  
CN Ethanone, 1-[4-[(2S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152018-90-1 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-26-5

CMF C23 H26 F N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 152018-91-2 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-27-6


CMF C24 H28 F N3 O2 S



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 152018-92-3 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(1H-indol-7-yl)oxy]propyl]-4-piperidinyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 151719-30-1  
CMF C23 H24 F N3 O2




CM 2

CRN 110-17-8

09/712,129

CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 152019-18-6 CAPLUS  
CN Isoquinoline, 5-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 151719-58-3  
CMF C24 H24 F N3 O2



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 152019-19-7 CAPLUS  
CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-[(6-methoxy-1H-indol-5-yl)oxy]propyl]-4-piperidinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 151719-59-4  
CMF C24 H26 F N3 O3



CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E

Double bond geometry as shown.




RN 152019-21-1 CAPLUS  
 CN Ethanone, 1-[4-[(2R)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (97I) (CA INDEX NAME)

CM 1

CRN 151719-61-8  
 CMF C25 H29 F N2 O4  
 CDES 1:R

Absolute stereochemistry.




CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E

09/712,129

Double bond geometry as shown.



RN 152019-23-3 CAPLUS

CN Ethanone, 1-[4-[(2S)-3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methylpropoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 151719-63-0

CMF C25 H29 F N2 O4

CDES 1:S

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.



A17 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2001 ACS  
 AN 1993:7233 CAPLUS  
 DN 118:7233  
 TI N-(aryloxyalkyl)heteroaryl-8-azabicyclo[3.2.1]octanes, intermediates and a process for the preparation thereof and their use as medicaments  
 IN Glamkowski, Edward J.; Fink, David M.; Kurys, Barbara E.  
 PA Hoechst-Roussel Pharmaceuticals Inc., USA  
 SO Eur. Pat. Appl., 31 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 498331	A1	19920812	EP 1992-101706	19920203
	EP 498331	B1	19960522		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
	FI 9200435	A	19920805	FI 1992-435	19920131
	CA 2060573	AA	19920805	CA 1992-2060573	19920203
	NO 9200438	A	19920805	NO 1992-438	19920203
	AU 9210605	A1	19920806	AU 1992-10605	19920203
	AU 641842	B2	19930930		
	HU 60494	A2	19920928	HU 1992-321	19920203
	HU 207863	B	19930628		
	ZA 9200753	A	19921028	ZA 1992-753	19920203
	JP 05059049	A2	19930309	JP 1992-17668	19920203
	JP 08009613	B4	19960131		
	HU 62295	A2	19930428	HU 1992-3977	19920203
	HU 217616	B	20000328		
	PL 169092	B1	19960531	PL 1992-293363	19920203
	AT 138377	E	19960615	AT 1992-101706	19920203
	ES 2089255	T3	19961001	ES 1992-101706	19920203
	IL 100861	A1	19970218	IL 1992-100861	19920203
	RU 2075479	C1	19970320	RU 1992-5010691	19920203
	CZ 284754	B6	19990217	CZ 1992-297	19920203
PRAI	US 1991-650144	A	19910204		
	HU 1992-321	A3	19920203		
OS	MARPAT 118:7233				
GI					



I

AB The title compds. I (X = O, S, NH; Y = H, halo, alkoxy; p = 1, 2; n = 2-4; R = H, alkyl, alkoxy, HO, halo, H2N, alkylamino, O2N, alkylthio, F3CO, cyano, F3C, alkylcarbonyl, R1-substituted aryl; R1 = H, alkyl, alkoxy,


halo, HO, HO<sub>2</sub>C, alkylamino, O<sub>2</sub>N, alkylthio, cyano, F<sub>3</sub>C; m = 1,2) salts and isomers thereof, useful as antipsychotics and antidepressants, are prepd. BF<sub>3</sub>.Et<sub>2</sub>O was added to 2,4-F<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH(OMe)<sub>2</sub> and P(OEt)<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> to give a di-Et phosphonate deriv. which was condensed with tropinone, oximated, cyclized to a benzisoxazolylazabicyclooctane deriv., demethylated, and heated with 4,3-[Cl(CH<sub>2</sub>)<sub>3</sub>O] (MeO)C<sub>6</sub>H<sub>3</sub>COMe and HCl/EtOH to give I.HCl (Y<sub>p</sub> = 6-F, X = O, n = 3, R<sub>m</sub> = 2-MeO, 4-Ac) (II). Antipsychotic activity was detd. by a climbing assay, in which the ED<sub>50</sub> of II was 5.0 mg/kg, i.p.

IT 144062-09-9P 144062-10-2P 144062-11-3P  
 144062-12-4P 144062-13-5P 144062-14-6P  
 144062-15-7P 144062-16-8P 144062-17-9P  
 144062-18-0P 144062-19-1P 144062-20-4P  
 144062-21-5P 144062-22-6P 144062-23-7P  
 144253-62-3P 144253-63-4P 144253-64-5P  
 144253-65-6P 144253-66-7P 144253-67-8P  
 144253-68-9P 144253-69-0P 144253-70-3P  
 144253-71-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as antidepressant and antipsychotic)


RN 144062-09-9 CAPLUS

CN Ethanone, 1-[4-[4-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-10-2 CAPLUS

CN Ethanone, 1-[4-[3-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-11-3 CAPLUS

CN Ethanone, 1-[4-[3-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-12-4 CAPLUS

CN Ethanone, 1-[4-[2-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




09/712,129


RN 144062-13-5 CAPLUS  
CN Ethanone, 1-[4-[2-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 144062-14-6 CAPLUS  
CN Ethanone, 1-[4-[4-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-15-7 CAPLUS  
CN Ethanone, 1-[4-[3-[3-(1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-16-8 CAPLUS

CN Ethanone, 1-[4-[2-[3-(1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-17-9 CAPLUS

CN Ethanone, 1-[4-[4-[3-(1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-18-0 CAPLUS

CN Ethanone, 1-[4-[2-[3-(6-fluoro-1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-19-1 CAPLUS

CN Ethanone, 1-[4-[4-[3-(6-fluoro-1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-20-4 CAPLUS

CN Ethanone, 1-[4-[3-[3-(6-fluoro-1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-21-5 CAPLUS

CN Ethanone, 1-[4-[2-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 144062-22-6 CAPLUS

CN Ethanone, 1-[4-[3-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 144062-23-7 CAPLUS


CN Ethanone, 1-[4-[4-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



09/712,129

RN 144253-62-3 CAPLUS


CN Ethanone, 1-[4-[4-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 144253-63-4 CAPLUS

CN Ethanone, 1-[4-[3-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 144253-64-5 CAPLUS

CN Ethanone, 1-[4-[3-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144062-11-3

CMF C26 H30 N2 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 144253-65-6 CAPLUS

CN Ethanone, 1-[4-[2-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144062-12-4

CMF C25 H27 F N2 O4




09/712,129

CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 144253-66-7 CAPLUS  
CN Ethanone, 1-[4-[2-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 144062-13-5  
CMF C25 H28 N2 O4



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 144253-67-8 CAPLUS  
CN Ethanone, 1-[4-[4-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

09/712,129

CM 1


CRN 144062-14-6  
CMF C27 H31 F N2 O4



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 144253-68-9 CAPLUS  
CN Ethanone, 1-[4-[4-[3-(1H-indazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144062-17-9  
CMF C27 H33 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 144253-69-0 CAPLUS

CN Ethanone, 1-[4-[2-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144062-21-5

CMF C25 H28 N2 O3 S




09/712,129

CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 144253-70-3 CAPLUS  
CN Ethanone, 1-[4-[3-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]propoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 144062-22-6  
CMF C26 H30 N2 O3 S



CM 2


CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.



RN 144253-71-4 CAPLUS  
CN Ethanone, 1-[4-[4-[3-(1,2-benzisothiazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

09/712,129





● HCl

09/712,129

L17 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2001 ACS  
AN 1991:408826 CAPLUS  
DN 115:8826  
TI Preparation of [(N-thiazolylpiperazino)ethyl] 4-ethoxycarbonylphenyl ethers and analogs as antirhinoviral agents  
IN Stokbroekx, Raymond Antoine; Grauwels, Gilbert Arthur Jules; Willems, Marc  
PA Janssen Pharmaceutica N. V., Belg.  
SO Eur. Pat. Appl., 44 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 398425	A1	19901122	EP 1990-201184	19900510
	EP 398425	B1	19940316		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AU 9054941	A1	19901115	AU 1990-54941	19900510
	AU 628172	B2	19920910		
	AT 102929	E	19940415	AT 1990-201184	19900510
	ES 2053077	T3	19940716	ES 1990-201184	19900510
	CA 2016742	AA	19901115	CA 1990-2016742	19900514
	ZA 9003664	A	19920129	ZA 1990-3664	19900514
	IL 94382	A1	19941111	IL 1990-94382	19900514
	JP 03047174	A2	19910228	JP 1990-125260	19900515
PRAI	US 1989-351697		19890515		
	US 1989-351698		19890515		
	EP 1990-201184		19900510		
OS	MARPAT 115:8826				
GI					



AB Title compds. I [R = (substituted) heterocyclyl; R1, R2 = H, C1-4 alkyl, halo; R3 = H, halo, cyano, C1-4 alkoxy, aryl, R4O2C, R4 = H, C1-4 alkyl, aryl-C1-4-alkyl, C3-5 alkenyl, etc.; X = N, CH; Z = C1-4 alkanediyl; m, n = 1-4; m + n = 3-5], an addn. salt or stereochem. isomer thereof, are prep'd. Et 2-bromo-4-thiazolecarboxylate, Et 4-[2-(1-piperazinyl)ethoxy]benzoate (prepn. given), and NaCO3 were stirred for 5 h at 160.degree. to give title compd. II which had IC50 of 9 ng/mL against certain serotypes of the human rhinovirus.

IT 133310-99-3P 133311-00-9P 133311-19-0P  
133311-27-0P 133311-28-1P 133311-29-2P


09/712,129

133311-30-5P 133311-31-6P 133333-58-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as rhinovirucide)


RN 133310-99-3 CAPLUS

CN Benzoic acid, 4-[2-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 133311-00-9 CAPLUS

CN 1,2-Benzisothiazole, 3-[4-[3-(2-chloro-4-methoxyphenoxy)propyl]-1-piperazinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 133311-19-0 CAPLUS

CN Benzoic acid, 4-[3-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 133311-27-0 CAPLUS

CN 1,2-Benzisothiazole, 3-[4-[3-(2-chloro-4-methoxyphenoxy)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 133311-28-1 CAPLUS

CN 1,2-Benzisoxazole, 3-[4-[2-(2-chloro-4-methoxyphenoxy)ethyl]piperazinyl]- (9CI) (CA INDEX NAME)




RN 133311-29-2 CAPLUS

CN 1,2-Benzisoxazole, 3-[4-[3-(2-chloro-4-methoxyphenoxy)propyl]piperazinyl]- (9CI) (CA INDEX NAME)




RN 133311-30-5 CAPLUS

CN Benzoic acid, 4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 133311-31-6 CAPLUS

CN Benzoic acid, 4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 133333-58-1 CAPLUS

CN Benzoic acid, 4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




09/712,129

applicants

L17 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2001 ACS  
AN 1991:185553 CAPLUS  
DN 114:185553  
TI Preparation of N-(aryloxyalkyl)heteroarylpiperidines and  
-heteroarylpiperazines as antipsychotic agents  
IN Strupczewski, Joseph Thomas; Helsley, Grover Cleveland; Chiang, Yulin;  
Bordeau, Kenneth J.  
PA Hoechst-Roussel Pharmaceuticals, Inc., USA  
SO Eur. Pat. Appl., 56 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 402644	A1	19901219	EP 1990-109208	19900516
	EP 402644	B1	19950816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2076253	T3	19951101	ES 1990-109208	19900516
	DD 300433	A5	19920611	DD 1990-340772	19900517
	CZ 232385	B6	19970716	CZ 1990-2425	19900517
	SK 279474	B6	19981104	SK 1990-2425	19900517
	CA 2017193	AA	19901119	CA 1990-2017193	19900518
	NO 9002214	A	19901120	NO 1990-2214	19900518
	NO 177301	B	19950515		
	NO 177301	C	19950823		
	ZA 9003830	A	19910227	ZA 1990-3830	19900518
	JP 03063263	A2	19910319	JP 1990-127090	19900518
	JP 05062580	B4	19940817		
	HU 58720	A2	19920330	HU 1990-3090	19900518
	HU 218200	B	20000628		
	PL 163965	B1	19940531	PL 1990-285247	19900518
	RU 2062776	C1	19960627	RU 1990-4743876	19900518
	RU 2147583	C1	20000420	RU 1995-115403	19900518
	CN 1048037	A	19901226	CN 1990-103721	19900519
	AU 9055770	A1	19901122	AU 1990-55770	19900523
	AU 640653	B2	19930902		
	CZ 268464	B6	20010613	CZ 1996-3628	19961210
	FI 9901869	A	19990902	FI 1999-1869	19990902
	CN 1305812	A	20010801	CN 2000-130979	20001116
PRAI	US 1989-354411	A	19890519		
	US 1989-456790	A	19891229		
OS	MARPAT	114:185553			
GI					




**AB** The title compds. I [R = Q; X = O, S, (substituted) NH; p = 1,2; Y = H, C1-6 alkyl, OH, Cl, F, Br, iodo, C1-6 alkoxy, CF3, NO2, NH2; when p = 1, Y = alkoxy; when p = 2, X = O; Z = CH, N; n = 2-5; R1 = H, alkyl, C1-6 alkoxy, OH, CO2H, Cl, F, Br, iodo, NO2, mono- or dialkylamino, CF3, cyano, CONH2, alkanoyl, aroyl, (substituted) Ph, etc.], having antipsychotic and/or analgesic activity, are prep'd. by reaction of I (R = H) with phenoxyalkyl halides QX1 (X1 = Cl, Br). Thus, a mixt. of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole-HCl, 1-[4-(3-chloropropoxy)-3-methoxyphenyl]ethanone, and K2CO3 in DMF was stirred 16 h at 90.degree. to give 58% a benzisoxazole (II). A total of 53 I were prep'd. II inhibited the apomorphine-induced climbing behavior in mice with ED50 of 0.095 mg/kg, i.p.

**IT** 133454-45-2P 133454-46-3P 133454-47-4P  
 133454-48-5P 133454-49-6P 133454-51-0P  
 133454-53-2P 133454-54-3P 133454-55-4P  
 133454-56-5P 133454-57-6P 133454-58-7P  
 133454-59-8P 133454-60-1P 133454-61-2P  
 133454-63-4P 133454-64-5P 133454-66-7P  
 133454-67-8P 133454-68-9P 133454-69-0P  
 133454-71-4P 133454-72-5P 133454-73-6P  
 133454-75-8P 133454-76-9P 133454-78-1P  
 133454-79-2P 133454-80-5P 133454-81-6P  
 133454-82-7P 133454-84-9P 133454-85-0P  
 133454-87-2P 133454-88-3P 133454-89-4P  
 133454-90-7P 133454-91-8P 133454-92-9P  
 133454-93-0P 133454-94-1P 133454-95-2P  
 133454-96-3P 133454-97-4P 133454-99-6P  
 133455-00-2P 133455-02-4P 133455-03-5P  
 133455-04-6P 133455-05-7P 133455-06-8P  
 133455-07-9P 133483-85-9P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as analgesic and antipsychotic)

**RN** 133454-45-2 CAPLUS


**CN** Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-46-3 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-47-4 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-48-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(4-(1,2-benzisoxazol-3-yl)-1-piperidinyl)butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-49-6 CAPLUS

09/712,129

CN Ethanone, 1-[4-[4-[6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-51-0 CAPLUS

CN Ethanone, 1-[4-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-50-9

CMF C23 H26 N2 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 133454-53-2 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-52-1


CMF C24 H30 N4 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-54-3 CAPLUS  
CN Ethanone, 1-[4-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-55-4 CAPLUS  
CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 133454-56-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-57-6 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-58-7 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-59-8 CAPLUS

CN Ethanone, 1-[4-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




09/712,129

RN 133454-60-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-61-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-63-4 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-62-3  
CMF C25 H29 Cl N2 O4




CM 2

CRN 110-17-8  
CMF C4 H4 O4

09/712,129


CDES 2:E

Double bond geometry as shown.



RN 133454-64-5 CAPLUS

CN Ethanone, 1-[4-[3-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-66-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-65-6

CMF C22 H25 F N2 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-67-8 CAPLUS

CN Methanone, [3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 133454-68-9 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1H-indazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-69-0 CAPLUS

CN Ethanone, 1-[4-[2-[4-(6-chloro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-71-4 CAPLUS

CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-70-3

CMF C23 H25 F N2 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 133454-72-5 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 133454-73-6 CAPLUS

CN Ethanone, 1-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-5-methylphenyl]- (9CI) (CA INDEX NAME)




RN 133454-75-8 CAPLUS

CN Acetamide, N-[3-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-4-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-74-7


CMF C24 H28 F N3 O4




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 133454-76-9 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-78-1 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methylphenyl]-, (2E)-2-butenedioate (2:1) (9CI)  
(CA INDEX NAME)

CM 1


CRN 133454-77-0  
CMF C24 H27 F N2 O3




CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.




RN 133454-79-2 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133454-80-5 CAPLUS  
CN Ethanone, 1-[4-[3-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-81-6 CAPLUS  
CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-82-7 CAPLUS  
 CN Ethanone, 1-[4-[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl- (9CI) (CA INDEX NAME)




RN 133454-84-9 CAPLUS  
 CN 1H-Indazole, 3-[4-[3-(4-acetyl-2-methoxyphenoxy)propyl]-1-piperazinyl]-1-benzoyl-6-fluoro-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-83-8

CMF C30 H31 F N4 O4




CM 2

CRN 110-17-8


CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 133454-85-0 CAPLUS  
 CN Ethanone, 1-[4-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-87-2 CAPLUS  
 CN Ethanone, 1-[4-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-3-methoxyphenyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133454-86-1  
 CMF C23 H27 N3 O3 S




CM 2

CRN 110-17-8  
 CMF C4 H4 O4  
 CDES 2:E

Double bond geometry as shown.




RN 133454-88-3 CAPLUS  
 CN Ethanone, 1-[3,5-dibromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 133454-89-4 CAPLUS

CN Ethanone, 1-[4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-90-7 CAPLUS

CN 1,2-Benzisoxazole, 6-fluoro-3-[1-(3-phenoxypropyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 133454-91-8 CAPLUS


CN Ethanone, 1-[4-[2-[4-(6-chloro-1H-indazol-3-yl)-1-piperazinyl]ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-92-9 CAPLUS


CN Ethanone, 2,2,2-trifluoro-1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133454-93-0 CAPLUS

CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 133454-94-1 CAPLUS

CN Ethanone, 1-[4-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133454-95-2 CAPLUS


CN Methanone, [4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]phenyl- (9CI) (CA INDEX NAME)



09/712,129


RN 133454-96-3 CAPLUS

CN Ethanone, 1-[3-bromo-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133454-97-4 CAPLUS

CN 1,2-Benzisoxazole, 3-[1-[3-[4-(1-ethoxyethyl)-2-methoxyphenoxy]propyl]-4-piperidinyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 133454-99-6 CAPLUS

CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester), (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 133454-98-5

CMF C26 H31 F N2 O5




CM 2


09/712,129

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E

Double bond geometry as shown.




RN 133455-00-2 CAPLUS  
CN 1-Pantanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 133455-02-4 CAPLUS  
CN Benzenamine, 2-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-N-methyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 133455-01-3  
CMF C22 H26 F N3 O2



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 133455-03-5 CAPLUS


09/712,129

CN 1,2-Benzisoxazole, 3-[1-[3-(4-bromo-2-methoxyphenoxy)propyl]-4-piperidinyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 133455-04-6 CAPLUS

CN 1-Propanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 133455-05-7 CAPLUS

CN Benzamide, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 133455-06-8 CAPLUS


CN Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 133455-07-9 CAPLUS  
CN Ethanone, 1-[3-ethoxy-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 133483-85-9 CAPLUS  
CN Benzonitrile, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



IT 133454-98-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, in prepn. of analgesic and antipsychotic)  
RN 133454-98-5 CAPLUS  
CN Benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-.alpha.-methyl-, acetate (ester) (9CI) (CA INDEX NAME)






(2-HO<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>S)<sub>2</sub> was treated with SOCl<sub>2</sub> to give 71% (2-ClCO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>S)<sub>2</sub> which was cyclocondensed with aq. NH<sub>4</sub>OH in presence of Cl to give 88.5% benzisothiazolone II (R<sub>5</sub>R<sub>6</sub> = O, R<sub>7</sub> = H). This was chlorinated with POCl<sub>3</sub> to give 77% II (R<sub>5</sub> = Cl, R<sub>6</sub>R<sub>7</sub> = bond). The latter was aminolyzed with piperidine to give 68% I (R<sub>1</sub>-R<sub>4</sub> = H).

IT 103485-89-8P 103485-90-1P 103485-91-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as analgesic)


RN 103485-89-8 CAPLUS

CN 1,2-Benzisothiazole, 3-[4-(2-phenoxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 103485-90-1 CAPLUS

CN 1,2-Benzisothiazole, 3-[4-(4-phenoxybutyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 103485-91-2 CAPLUS


CN 1,2-Benzisothiazole, 3-[4-(4-phenoxybutyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

09/712,129

~~LM~~ ANSWER 23 OF 24 CAPLUS COPYRIGHT 2001 ACS  
~~AT~~ 1985:203897 CAPLUS  
DN 102:203897  
TI Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles  
AU Strupczewski, Joseph T.; Allen, Richard C.; Gardner, Beth Ann; Schmid, Blaine L.; Stache, Ulrich; Glamkowski, Edward J.; Jones, Michael C.; Ellis, Daniel B.; Huger, Francis P.; Dunn, Robert W.  
CS Chem. Res. Dep., Hoechst-Roussel Pharm., Inc., Somerville, NJ, 08876, USA  
SO J. Med. Chem. (1985), 28(6), 761-9  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
OS CASREACT 102:203897  
GI



I


AB The synthesis of a series of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles is described. The neuroleptic activity of the series was evaluated by utilizing the climbing mice assay and inhibition of [<sup>3</sup>H]spiroperidol binding. Structure-activity relationships were studied by variation of the substituent on the benzisoxazole ring with concomitant variation of 4 different 1-piperidinyl substituents. Max. neuroleptic activity was realized when there was a 6-F substituent on the benzisoxazole ring. The 1-piperidinyl substituent appeared less significant, although in most cases, the (1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)propyl group imparted max. potency. The most potent compd. in both assays was piperidinylbenzisoxazole I.

IT 84163-21-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prep. and deblocking of)

RN 84163-21-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2-benzisoxazol-3-yl)-, phenyl ester  
(9CI) (CA INDEX NAME)



09/12,129


L17 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2001 ACS  
AN 1983:53870 CAPLUS  
DN 98:53870  
TI 3-(4-Piperidyl)-1,2-benzisoxazoles  
IN Strupczewski, Joseph T.; Gardner, Beth Ann; Allen, Richard C.  
PA Hoechst-Roussel Pharmaceuticals, Inc., USA  
SO U.S., 21 pp.  
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4355037	A	19821019	US 1981-319871	19811112
	US 4408053	A	19831004	US 1982-405965	19820806
	US 4408054	A	19831004	US 1982-407235	19820811
	EP 80104	A2	19830601	EP 1982-110318	19821109
	EP 80104	A3	19830824		
	EP 80104	B1	19881214		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 39251	E	19881215	AT 1982-110318	19821109
	ES 517245	A1	19840616	ES 1982-517245	19821110
	CA 1215066	A1	19861209	CA 1982-415352	19821110
	AU 8290390	A1	19830519	AU 1982-90390	19821111
	AU 567865	B2	19871210		
	JP 58090582	A2	19830530	JP 1982-196885	19821111
	JP 04011546	B4	19920228		
	ZA 8208281	A	19830928	ZA 1982-8281	19821111
	US 4469869	A	19840904	US 1983-492846	19830509
	US 4528376	A	19850709	US 1983-492767	19830509
	ES 529370	A1	19850901	ES 1984-529370	19840201
	ES 529369	A1	19850916	ES 1984-529369	19840201
	US 4408054	B1	19870602	US 1986-90001062	19860801
	AU 8811385	A1	19880519	AU 1988-11385	19880208
	AU 612621	B2	19910718		
PRAI	US 1981-319871		19811112		
	US 1982-407235		19820811		
	EP 1982-110318		19821109		
OS	CASREACT	98:53870			
GI					



I

AB Analgesic benzisoxazoles I [R = H, alkyl, alkenyl, cycloalkylalkyl, phenylalkyl, HO, dialkylaminoalkyl, cyano, cyanomethyl, Bz, COR2 (R2 = H, alkyl, PhO, PhCH2O); R1 = H, alkyl, halo, HO, alkoxy; n = 1, 2] and their pharmaceutically acceptable salts were prep'd. Thus, 1-methyl-4-(2-


fluorobenzoyl)piperidine was cyclized with HONH<sub>2</sub> to give I (R = Me, R<sub>1</sub> = H).HCl (II). The analgesic ED<sub>50</sub> of II in the phenyl-p-quinone writhing assay in mice was 0.415 mg/kg.

IT 84163-19-9P 84163-21-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 84163-19-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(4-fluoro-1,2-benzisoxazol-3-yl)-, phenyl ester (9CI) (CA INDEX NAME)



RN 84163-21-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2-benzisoxazol-3-yl)-, phenyl ester (9CI) (CA INDEX NAME)

